[STUDY_ID_REMOVED]
CONFIDENTIAL Protocol 2007-301-[ADDRESS_427315]-T-01-01 v3.0Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment 2
Amendment 1June 2020February 2020
Original Protocol July 2019
Amendment 2 (June 2020)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
because it neither significantly impacts the safety or physical/mental integrity of participants nor 
the scientific value of the study.
Overall Rationale for the Amendment:
The rationale for changes implemented in Protocol Amendment [ADDRESS_427316], and to remove an error related to OSDI scores.
Section Number and Name [CONTACT_19523] 5.1 Inclusion Criteria, 
Inclusion Criterion 2.01Added need not be the same eye at Screening and BaselineClarification
Section 5.1 Inclusion Criteria, Inclusion Criterion 2.02Added need not be the same eye at 
Screening and Baseline or the same eye 
that meets Inclusion Criterion 2.01Clarification
Section 5.2 Exclusion Criteria, 
Exclusion Criterion 1.02Removed the lower bound of < 5 for the total cornea staining score, and changed application of the criterion 
from one or both eyes to either eyeClarification to prevent potential 
corneal staining scores from conflicting with inclusion criterion 
2.01
Section [IP_ADDRESS] Ocular Surface Disease Index QuestionnaireRemoved sentence that reiterated entry 
criteria related to the OSDI score and 
contained an error (> 65)Clarification to avoid unnecessarily repeating entry criteria language
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427317] of Figures................................................................................................................ ..................6
1. Protocol Summary ............................................................................................................. .....7
1.1. Synopsis ......................................................................................................................7
1.2. Schema........................................................................................................................81.3. Schedule of Activities (SoA) ....................................................................................10
2. Introduction...........................................................................................................................12
2.1. Study Rationale.........................................................................................................122.2. Background...............................................................................................................122.3. Benefit/Risk Assessment ..........................................................................................13
3. Objectives and Endpoints ..................................................................................................... 15
4. Study Design................................................................................................................. ........16
4.1. Overall Design ..........................................................................................................164.2. Scientific Rationale for Study Design.......................................................................164.3. Justification for Dose ................................................................................................164.4. End of Study Definition............................................................................................17
5. Study P opulation...................................................................................................................18
5.1. Inclusion Criteria ......................................................................................................185.2. Exclusion Criteria .....................................................................................................205.3. Lifestyle Considerations ...........................................................................................235.4. Screen Failures..........................................................................................................23
6. Study Intervention.................................................................................................................24
6.1. Study Interventions Administered ............................................................................24
6.1.1. Run-in Medications and Administration....................................................246.1.2. Study Supplies ...........................................................................................256.1.3. Instructions for Use and Administration....................................................25
6.2. Preparation/Handling/Storage/Accountability..........................................................266.3. Measures to Minimize Bias: Randomization and Masking ......................................266.4. Study Interven tion Compliance ................................................................................27
6.5. Concomitant Therapy................................................................................................27
6.5.1. Prohibited Treatments and Washout Before the 
Study ..........................................................................................................28
6.5.2. Permitted Treatments.................................................................................286.5.3. Prohibited Treatments During the Study ...................................................296.5.4. Rescue Medicine........................................................................................30
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427318]-T-01-01 v3.06.6. Dose Modification ....................................................................................................30
6.7. Intervention after the End of the Study.....................................................................30
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal.................................................................................................317.1. Discontinuation of Study Intervention......................................................................317.2. Participant Discontinuation/Withdrawal from the Study..........................................317.3. Lost to Follow-Up.....................................................................................................32
8. Study Assessments and Procedures ......................................................................................32
8.1. Efficacy Assessments................................................................................................33
8.1.1. Primary Efficacy  Assessment ....................................................................34
[IP_ADDRESS]. Total Staining..............................................................................34
8.1.2. Secondary Efficacy Assessment ................................................................34
[IP_ADDRESS]. Current Symptom Survey ...........................................................34
8.1.3. Other Efficacy  Assessments ......................................................................35
[IP_ADDRESS]. Tear Break-up Time (with Fluorescein) .....................................[IP_ADDRESS]. Corneal Staining (Modified NEI Grading 
Scheme, with Fluorescein)..........................................................35
[IP_ADDRESS]. Conjunctival Staining (Modified NEI 
Grading Scheme, with Lissamine Green) ...................................36
[IP_ADDRESS]. Schirmer Test (with Anesthesia).................................................[IP_ADDRESS]. Ocular Surface Disease Index 
Questionnaire ..............................................................................38
[IP_ADDRESS]. Study Eye Drop Experience and 
Tolerability Questionnaire ..........................................................40
[IP_ADDRESS]. Functional Vision Questionnaire ................................................[IP_ADDRESS]. 5-Minute Blurry Vision and Ocular 
Discomfort Questionnaire...........................................................[ADDRESS_427319].................................................................................468.2.5. Intraocular Pressure (with Anesthesia and 
Fluorescein)................................................................................................46
8.3. Adverse Events and Serious Adverse Events ...........................................................47
8.3.1. Time Period and Frequency for Collecting AE and 
SAE Information........................................................................................47
8.3.2. Method of Detecting AEs and SAEs .........................................................478.3.3. Follow-up of AEs and SAEs......................................................................488.3.4. Regulatory Reporting Requirements for SAEs..........................................488.3.5. Pregnancy...................................................................................................488.3.6. Medication Errors ......................................................................................49
8.4. Treatment of Overdose .............................................................................................49
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427320]-T-01-01 v3.08.5. Pharmacokinetics ......................................................................................................49
8.6. Pharmaco dynamics ...................................................................................................49
8.7. Genetics................................................................................................................... ..49
8.8. Biomarkers and Other Assessments..........................................................................49
8.8.1. Study Eye Drop Usage Questionnaire .......................................................49
8.9. Health Economics .....................................................................................................50
9. Statistical Considerations................................................................................................... ...51
9.1. Statistical Hypotheses ...............................................................................................519.2. Sample Size Determination.......................................................................................519.3. Populations for Analyses ..........................................................................................519.4. Statistical Analyses ...................................................................................................52
9.4.1. Efficacy Analyses ......................................................................................52
[IP_ADDRESS]. Analysis Endpoints .....................................................................[IP_ADDRESS]. Primary Analyses........................................................................[IP_ADDRESS]. Secondary Analyses....................................................................[IP_ADDRESS]. Other Efficacy Analyses .............................................................53
9.4.2. Safety Analyses..........................................................................................53
[IP_ADDRESS]. Adverse Events ...........................................................................54
9.4.3. Other Safety  Anal yses................................................................................54
[IP_ADDRESS]. Subgroup Analyses .....................................................................54
9.5. Interim Analyses .......................................................................................................54
9.5.1. Data Monitoring Committee......................................................................55
10. Supporting Documentation and Operational Considerations ...............................................56
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations...........................................................................................................5610.1.1. Regulatory and Ethical Considerations......................................................5610.1.2. Financial Disclosure...................................................................................5610.1.3. Informed Consent Process .........................................................................5710.1.4. Data Protection...........................................................................................5710.1.5. Posting Clin ical Study Data.......................................................................57
10.1.6. Data Qualit y Assurance .............................................................................58
10.1.7. Source Documents .....................................................................................5810.1.8. Study and Site Closure...............................................................................5810.1.9. Publication Policy......................................................................................5910.1.10. Compliance with Protocol..........................................................................59
10.2. Appendix 2: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting ...................................................60Definition of AE .......................................................................................................60Definition of SAE .....................................................................................................61Recording and Follow-up of AEs and/or SAEs........................................................62Reporting of SAEs ....................................................................................................64
10.3. Appendix 3: Abbreviations.......................................................................................6510.4. Appendix 4: Standard Discontinuation Criteria........................................................67
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427321]-T-01-01 v3.010.5. Appendix 5: Study  Tabular Summary ......................................................................69
10.6. Appendix 6: Contraceptive Guidance and Collection of 
Pregnancy Information..............................................................................................71
Definitions: ...............................................................................................................71Contraception Guidance: ..........................................................................................71Pregnancy Testing:....................................................................................................73Collection of Pregnancy Information: ......................................................................73
10.7. Appendix 9: Study Schedule Supplement.................................................................74
10.7.1. Screening (Day -7 [-3 days])......................................................................7410.7.2. Baseline (Day 1) ........................................................................................7410.7.3. Day 7 (±3 days)..........................................................................................7510.7.4. Days 30 and 60 (±7 days) ..........................................................................7510.7.5. Day 90/Early Exit (±7 days) ......................................................................76
10.8. Appendix 10: Protocol Amendment History ............................................................[ADDRESS_427322] of Figures
Figure 1-1 Study Schema.......................................................................................................... 9
Figure 8-1 Modified NEI Grading Scheme Part 1: Corneal Staining Grading Scheme......... 36Figure 8-2 Modified NEI Grading Scheme Part 2: Conjunctival Staining Grading Scheme. 37
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427323]-T-01-01 v3.01. Protocol Summary
1.1. Synopsis
Protocol Title: A Multicenter, Single-masked, Randomized Study to Compare the Efficacy and 
Safety of a New Artificial Tear Formulation (011516X) with Systane®Ultra Multidose for 90 
Days in Participants with Dry Eye Disease
Protocol Number: 2007-301-005
Brief Title: Efficacy and safety of a new artificial tear formulation compared with Systane Ultra 
multidose in participants with dry eye diseaseStudy Phase: 3
Study Rationale: The purpose of this study is to evaluate the efficacy and safety of a new
artificial tear formulation (NATF; 011516X) compared with Systane
®Ultra multidose (MD) in 
participants with dry eye disease (DED). This study will provide final guidance towards selection 
of the formulation for commercialization and will support Allergan quality standards and product requirements.
Objectives and Endpoints:
Objectives Measures
Primary
!To evaluate the efficacy and safety of 
011516X in participants with signs and 
symptoms of DED compared with 
Systane Ultra MDPrimary Efficacy Measure
!Total staining (sum of corneal and conjunctival staining) 
Secondary Efficacy Measure
!Current Symptom Survey 
Other Efficacy Measures
!Corneal staining (modified National Eye Institute [NEI] 
grading scheme, with fluorescein)
!Conjunctival staining (modified NEI grading scheme, with 
lissamine green)
!Tear break-up time (TBUT, with fluorescein)
!Schirmer test (with anesthesia)
!Ocular Surface Disease Index©(OSDI)
!Study Eye Drop Experience and Tolerability Questionnaire
!Functional Vision Questionnaire
!5-Minute Blurry Vision and Ocular Discomfort Questionnaire
Safety Measures
!Adverse events (AEs)
!Slit-lamp biomicroscopy
!Currently corrected distance visual acuity
!Best-corrected distance visual acuity (BCDVA)
!Intraocular pressure (IOP) (participants with glaucoma or 
ocular hypertension [OHT] only)
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427324]-T-01-01 v3.0Overall Study Design:
This study is designed as a multicenter, single-masked, randomized, 2-arm, parallel-group study 
comparing the efficacy and safety of a NATF (011516X) with Systane Ultra MD (see Figure 1-1 ). All qualified study participants will receive REFRESH PLUS
®for approximately 7 
days during a run-in period prior to the Day 1 (Baseline) visit. If still qualified at the Day 1 (Baseline) visit, participants will then be randomized in a 1:1 ratio to use 011516X or Systane Ultra MD, with central stratification by [CONTACT_2006] 1 (Baseline) total ocular staining score of the study
eye (mild/moderate = score of 6 to 25 versus [vs] severe = score of 26 to 43). The primary
efficacy measure is total ocular staining and the primary analysis timepoint is at Day 90.
Number of Participants:
Approximately 400 participants (200 participants in each arm) will be randomized in order to 
have 340 participants (170 participants in each arm) complete the study through Day 90, assuming an approximate 15% dropout rate. Participants who prematurely discontinue from the study will not be replaced.
Number of Sites:
The study will be conducted at approximately 28 sites in the [LOCATION_002] (US).
Intervention Groups and Study Duration:
All qualified study participants will receive REFRESH PLUS for approximately 7 days during a 
run-in period prior to the Day 1 (Baseline) visit. Participants will be instructed to instill 1 to 
2 drops of the run-in medication in each eye, 3 times per day for 7 days. If still qualified at the 
Day 1 (Baseline) visit, participants will then be randomized in a 1:1 ratio to use 011516X or Systane Ultra MD, with central stratification by [CONTACT_2006] 1 (Baseline) total ocular staining score of 
the study eye (mild/moderate = score of 6 to 25 vs severe = score of 26 to 43). Participants will 
be instructed to instill 1 to 2 drops of their assigned study intervention (investigational eye drops)in each eye, 3 times per day for approximately 90 days.
Data Monitoring Committee: There will be no Data Monitoring Committee for this study.
1.2. Schema
The study design is presented in Figure 1-1 .
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427325]-T-01-01 v3.01.3. Schedule of Activities (SoA)
Study procedures are recommended to be done in sequence as listed in the schedule below.
Study Day Screening 
(Day -7)Day 1
(Baseline) Day 7 Day 30 Day 60Day 90/ 
Early Exit Notes
Visit Window (-3 days) (±3 days) (±7 days) (±7 days) (±7 days)Each follow-up visit should be 
consistently scheduled within ±90 minutes of the time of the Day 1 (Baseline) visit.
Written informed consent and written documentation in accordance with the 
relevant country and local privacy 
requirements (HIPAA for US sites)X
Inclusion/exclusion criteria assessment X X
Demography X
Self-assessed surveys/questionnaires: Not performed if a participant reports use of a prohibited intervention. Does not apply to Screening visit.
Study Eye Drop Usage Questionnaire XXXX X
Current Symptom Survey X XXXX X
OSDI Questionnaire X XXXX X
Study Eye Drop Experience and Tolerability QuestionnaireXXX X
Functional Vision Questionnaire XXXX X
Medical and ophthalmic histories X X
Prestudy or concomitant medication assessmentX XXXX X
Urine pregnancy test (for females of childbearing potential only)XX
Currently corrected distance visual
acuityX XXXX X
Best-corrected distance visual acuity X X
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427326]-T-01-01 v3.0Study Day Screening 
(Day -7)Day 1
(Baseline) Day 7 Day 30 Day 60Day 90/ 
Early Exit Notes
Visit Window (-3 days) (±3 days) (±7 days) (±7 days) (±7 days)Each follow-up visit should be 
consistently scheduled within ±90 minutes of the time of the Day 1 
(Baseline) visit.
Biomicroscopy X XXXX X
Tear break-up time (with fluorescein) X XXXX X N ot performed if a participant reports 
use of a prohibited intervention. 
Corneal staining (modified NEI grading 
scheme, with fluorescein)X XXXX X N ot performed if a participant reports 
use of a prohibited intervention. 
Conjunctival staining (modified NEI grading scheme, with lissamine green)X XXXX X N ot performed if a participant reports 
use of a prohibited intervention. 
Schirmer test (with anesthesia) X XXXX X N ot performed if a participant reports 
use of a prohibited intervention. 
Intraocular Pressure (Goldmann applanation tonometer)X XXXX X A fter the Screening visit, this needs to 
be completed only for participants who are treated for glaucoma or ocular hypertension.
Adverse event assessment X XXXX X
Access IxRS X X X X X
Randomization X
Run-in medication dispensed X
Run-in medication returned X
Study intervention dispensed X X X
Predose and postdose 5-Minute Blurry Vision and Ocular Discomfort QuestionnaireX X Must be performed at least 20 minutes 
after anesthesia application. Not performed if a participant reports use of a prohibited intervention. 
Used and unused study interventionreturnedXX X
HIPAA = Health Insurance Portability and Accountability Act; IxRS = interactive response system; NEI = National Eye Institute; OSDI = ocular surface disease index; US = [LOCATION_002]
Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427327]-T-01-01 v3.02. Introduction
2.1. Study Rationale
The purpose of this study is to evaluate the efficacy and safety of a new artificial tear 
formulation (NATF; 011516X) compared with Systane®Ultra multidose (MD) in participants 
with dry eye disease (DED). This study will provide final guidance towards selection of the formulation for commercialization and will support Allergan quality standards and product requirements.
2.2. Background
Dry eye disease is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by [CONTACT_72069], in which tear film instabilityand hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities 
play etiological roles ( Craig 2017). An estimated [ADDRESS_427328] common reasons patients seek care with their eye care 
professional ( Behrens 2006, Stapleton 2017 ).
Mechanistically, DED is recognized as a disturbance of the lacrimal functional unit, an integrated system comprised of the ocular surface (cornea, conjunctiva, accessory lacrimal glands, and Meibomian glands), the main lacrimal glands, and the sensory and interconnecting 
innervation ( Stern 1998). The diagnosis and classification (ie, mild/moderate/severe) of DED is 
achieved by [CONTACT_344350] (ocular surface epi[INVESTIGATOR_81636] [corneal and 
conjunctival staining]), tear volume (Schirmer score), tear film stability (tear break-up time 
[TBUT]), and patient-reported symptoms (questionnaires such as the Ocular Surface Disease 
Index
©[OSDI] and Eye Dryness Score - V isual Analog Scale [EDS-VAS]) ( Wolffsohn 2017).
The normal tear film is a relatively stable, thin film composed of a superficial lipid layer and an 
aqueous layer intermixed with a mucus gel layer, which is partially adherent to the corneal and 
conjunctival surface epi[INVESTIGATOR_2130]. The tear film is important for lubrication, protection, and nourishment of the ocular surface and serves as the primary refractive surface of the eyes visual 
system. DED is a complex disease characterized by a dysfunction of 1 or more components of 
the tear film, leading to the loss of tear film stability, a hyperosmolar shift in the tear film osmotic balance, and/or an inadequate amount of fluid on the ocular surface. This is 
characterized by [CONTACT_344351]-up of the tear film and numerous symptoms, including 
burning/stinging, foreign body sensation, blurred vision and photophobia. 
DED is often brought about or exacerbated by a variety of adverse environmental conditions, 
including prolonged computer use (visual display terminal syndrome), excessive wind or air 
conditioning, and overheated or dry air. The majority of patients with DED are initially managed with artificial tears. Environmental modifications, lid compresses and scrubs, and the addition of 
essential fatty acids to the diet are often recommended as well. With advancing severity of DED, 
treatment options, if needed, can include topi[INVESTIGATOR_344332]-inflammatory
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427329]-T-01-01 v3.0medications, as well as surgical options ranging from insertion of punctal plugs to tarsorraphy of 
the eyelids ( Jones 2017).
The NATF (011516X) under investigation in this study is a sterile, buffered, preservative-free artificial tear solution that is designed to provide protection to the ocular surface and improve
symptoms of DED. The NATF 011516X is specifically formulated to relieve DED symptoms
such as burning, irritation, and eye dryness and to protect against further irritation. The NATF contains carboxymethylcellulose and glycerin as active ingredients that lubricate and moisturize 
the ocular surface. The solution also contains other inactive compatible solutes such as carnitine, 
erythritol, and trehalose. The NATF 011516X conforms to the US Food and Drug Administration (FDA) monograph on ophthalmic demulcents.
The comparator product is Systane Ultra MD from Alcon, which is currently one of the leading 
marketed artificial tear products in the US. Key ingredients in Systane Ultra MD include polyethylene glycol 400 (0.4%), propy lene glycol (0.3%), and hydroxypropyl guar. 
The purpose of this study is to evaluate the efficacy and safety of the NATF 011516X compared with Systane Ultra MD.
2.3. Benefit/Risk Assessment
To date, management and treatment of DED remains a large unmet medical need. Current 
mainstays include use of artificial tears and in more severe cases, tear retention (temporarily or 
permanently plugging the tear ducts) and anti-inflammatory therapi[INVESTIGATOR_014]. Each approach has its own risk-benefit ratio. Artificial tears have been used in DED for decades and have proven to be safe 
and effective for lubricating and protecting the ocular surface from further irritation and relieving 
DED symptoms. Very few adverse events (AEs) are generally reported with artificial tears, such as blurred vision, eye redness, discomfort or other irritation not present before use of artificial 
tears, increased light sensitivity, matting or stickiness of eyelashes, swelling of eyelids, and 
watering of eyes. Because the risk-benefit ratio with artificial tears is low, they have been recognized as the first-line DED management option in both historical and contemporarypractice ahead of the alternatives mentioned above.
Patients with DED generally present with ocular surface epi[INVESTIGATOR_344333]. These pathophysiological changes are 
generally accompanied by [CONTACT_4676]-reported symptoms of ocular surface discomfort, often 
described as dryness, burning, pain, blurred vision and grittiness.
For many people with DED symptoms, the regular use of artificial tears represents a suitable and 
affordable option. Artificial tears are used to lubricate the eyes and relieve burning, irritation, 
and eye dryness attributed to DED as well as protect against further irritation. The benefit of the new generation of artificial tears developed by [CONTACT_344352], thus providing a 
valuable option for patients with DED.
The use of artificial tears is safe and well-tolerated and there are no unexpected safety concerns, 
although common side effects may include the following: mild eye burning or irritation, itching 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427330]-T-01-01 v3.0or redness of eyes, watery eyes, blurred vision, unpleasant taste in mouth, and/or allergy to the 
product or its ingredients.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of 011516X may be found in the investigator’s brochure (IB).
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427331]-T-01-01 v3.03. Objectives and Endpoints
Objectives Measures
Primary
!To evaluate the efficacy and safety  of 011516X in 
participants with signs and symptoms of DED 
compared with Systane Ultra MDPrimary Efficacy Measure
!Total staining (sum of corneal and conjunctival 
staining) 
Secondary Efficacy Measure
!Current Symptom Survey
Other Efficacy Measures
!Corneal staining (modified National Eye Institute 
[NEI] grading scheme, with fluorescein)
!Conjunctival staining (modified NEI grading 
scheme, with lissamine green)
!Tear break-up time (TBUT, with fluorescein)
!Schirmer test (with anesthesia)
!OSDI
!Study Eye Drop Experience and Tolerability 
Questionnaire
!Functional Vision Questionnaire
!5-Minute Blurry Vision and Ocular Discomfort 
Questionnaire
Safety Measures
!AEs
!Slit-lamp biomicroscopy
!Currently corrected distance visual acuity
!Best-corrected distance visual acuity (BCDVA)
!Intraocular pressure (IOP) (participants with 
glaucoma or ocular hypertension [OHT] only)
Approval Date: 08-Jun-2020 17:02:44 (GMT )
19NOV2021 CSR 2007-301-[ADDRESS_427332]-T-01-01 v3.04. Study Design
4.1. Overall Design
This study is designed as a multicenter, single-masked, randomized, 2-arm, parallel-group study 
comparing the efficacy and safety of a NATF (011516X) with Systane Ultra MD (see 
Figure 1-1 ). All qualified study participants will receive REFRESH PLUS®for approximately 7 
days during a run-in period prior to the Day 1 (Baseline) visit. Participants will be instructed to 
instill 1 to 2 drops of the run-in medication in each eye, 3 times per day for 7 days. If still 
qualified at the Day 1 (Baseline) visit, participants will then be randomized in a 1:1 ratio to use 
011516X or Systane Ultra MD, with central stratification by [CONTACT_2006] 1 (Baseline) total ocular staining score of the study eye (mild/moderate = score of 6 to 25 vs severe = score of 26 to 43). 
Participants will be instructed to instill 1 to 2 drops of their assigned study intervention
(investigational eye drops) in each eye, 3 times per day for approximately 90 days. The primaryefficacy measure is total ocular staining and the primary analysis timepoint is at Day 90.
Approximately 400 participants (200 participants in each arm) will be enrolled at approximately
[ADDRESS_427333] 340 participants (170 participants in each arm) complete the study through Day 90, assuming an approximate 15% dropout rate. Participants who prematurelydiscontinue from the study will not be replaced.
4.2. Scientific Rationale for Study Design
This Phase [ADDRESS_427334] formulation contains the same active ingredients (carboxymethylcellulose and glycerin) 
as the currently marketed REFRESH OPTIVE products. The solution also contains other inactive compatible solutes such as carnitine, erythritol, and trehalose. 
The formulation of Systane Ultra MD incorporates hydroxypropyl-guar, and is currently the 
market leader.
The present study is designed to compare the relative relief of symptoms of DED between the 
formulations as well as to characterize the effect on ocular surface staining. In order to be able to show a reduction in DED symptoms and in ocular surface staining at Day 90, the inclusion 
criteria were selected to include a participant population with clinically significant ocular surface 
staining and symptoms of DED at the Screening (Day -7) and Day 1 (Baseline) visits. These participants are anticipated to have a clinically treatable condition with sufficient room for improvement.
4.3. Justification for Dose
The dosing regimen during the study will be to instill [ADDRESS_427335] and 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427336] completed the study if he/she has completed all phases of the 
study including the last visit (Day 90).
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427337] 340 participants (170 participants in each arm) complete the study, assuming an approximate 15% dropout rate.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
1. Age
1.[ADDRESS_427338] be ≥ 18 years of age
2. Type of Participant and Disease Characteristics
2.01 At the Screening (Day -7) and Baseline (Day 1) visits, at least [ADDRESS_427339] qualifywith both of the following ocular staining scores:
!Corneal staining score of ≥ 0 to ≤ 4 in each of the 5 zones with a total of ≥5 to 
≤19 based on the modified NEI grading scheme (score range = 0 to 5; graded in 
5 zones of the cornea for a total score range of 0 to 25)
!Conjunctival staining score of ≥ 0t o  ≤ 4 in each of the 6 zones with a total of ≥1 
based on the modified NEI grading scheme (score range = 0 to 5 per zone)
(Need not be the same eye at Screening and Baseline)
2.02 At the Screening (Day -7) and Baseline (Day 1) visits, have 3 consecutive TBUT 
tests of ≤ [ADDRESS_427340] 1 eye 
(Need not be the same eye at Screening and Baseline or the same eye that meets 
Inclusion Criterion 2.01)
2.03 At the Screening (Day -7) and Baseline (Day 1) visits, have a Current Symptom Survey total mean score of ≥ 25 
2.04 At the Screening (Day -7) visit, have an OSDI total score of ≥ 23; and at Baseline 
(Day 1) visit, have an OSDI total score of ≥ 18, with no more than 3 responses answered as not applicable (N/A)
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427341] for DED within 6 months of the 
Screening (Day -7) visit
2.[ADDRESS_427342] ability/agreement to continue to wear existing current spectacle correction during the study period (if applicable)
2.[ADDRESS_427343] 20/32 Snellen equivalent in each eye 
using the 3-meter LogMar chart, with current correction (if necessary) at Screening 
(Day -7) visit 
2.08 If using any form of topi[INVESTIGATOR_344334] (ie, RESTASIS®) or lifitegrast 
5% ophthalmic solution (Xiidra®), participants must be using the drops for ≥90 days 
prior to the Screening (Day -7) visit and plan to continue without change for the duration of the study
3. Sex
3.01 Male or female
4. Contraceptives
4.01 A female participant is eligible to participate if she is not pregnant (ie, has a negative in-office urine pregnancy test at Screening [Day -7] and does not verbally report pregnancy at the Day 1 [Baseline] visit; see Appendix 6 ), is not breastfeeding, and at 
least 1 of the following conditions applies:
a. A woman not of childbearing potential (WOCBP) as defined in Appendix 6
OR
b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 6
for the duration of the study
5. Informed Consent
5.01 Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
5.02 Written informed consent from the participant has been obtained prior to anystudy-related procedures
5.03 Written documentation has been obtained in accordance with the relevant country
and local privacy requirements, where applicable
Approval Date: 08-Jun-2020 17:02:44 (GMT )
19NOV2021 CSR 2007-301-[ADDRESS_427344]-T-01-01 v3.06. Other
6.01 Able, as assessed by [CONTACT_093], to understand and willing to complete all 
study-related questionnaires/surveys, follow study instructions and likely to complete all required study visits
5.2. Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
1. Medical Conditions
1.[ADDRESS_427345] uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the participant at risk through participation, or which would prevent 
or confound protocol-specified assessments (eg, hypertension and diabetes, Sjögren's 
syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiencydisease, etc.)
1.02 At the Screening (Day -7) or Baseline (Day 1) visits, either eye has
!Corneal staining score of 5 in any of the 5 zones or a total score of > 19 based on the modified NEI grading scheme (score range = 0 to 5; graded in 5 zones of the cornea for a total score range of 0 to 25)
or
!Conjunctival staining score of 5 in any of the 6 zones based on the modified NEI grading scheme (score range = 0 to 5 per zone)
1.[ADDRESS_427346] 90 days prior to the Screening (Day -7) visit and/or participant anticipates contact [CONTACT_344353]
1.[ADDRESS_427347] any scheduled or planned systemic surgery or procedure during the study, which in the investigator’s opi[INVESTIGATOR_1649], may impact the participant’s study participation
Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427348]-T-01-01 v3.01.05 Presence of 1 or more of the following ocular conditions:
!Active ocular infection or non-keratoconjunctivitis sicca (KCS) ocular inflammation
!Active ocular allergy
!History of recurrent herpes keratitis or active disease within 6 months prior to the 
Screening (Day -7) visit 
!Corneal disorder or abnormality that affects corneal sensitivity or normal spreading 
of the tear film (except superficial punctate keratitis)
!Severe blepharitis or obvious inflammation of the lid margin, which in the judgment of the investigator, may interfere with the interpretation of the study results
!Keratoconjunctivitis sicca secondary to the destruction of conjunctival goblet cells, such as occurs with vitamin A deficiency or scarring such as that with cicatricial pemphigoid, alkali burns, Stevens-Johnson syndrome, trachoma, or irradiation
!Substantial non-KCS keratitis with overlying corneal stain or other significant corneal findings not directly related to DED; in addition, participants with DED signs/symptoms (eg, filamentary keratitis) of a severity where topi[INVESTIGATOR_344335]
2. Prior/Concomitant Therapy
2.01 The start date of any systemic medication (including over-the-counter [OTC], herbal, 
prescription, or nutritional supplements) which may affect DED or vision is < 90 days prior to the Screening (Day -7) visit or a change in dosage is anticipated during the study. Systemic medications, which may affect DED or vision, include but are not limited to the following: flax seed oil, fish oil, omega-[ADDRESS_427349] occlusion of the lacrimal puncta for either eye, with punctal plugs or cauterization 
< 6 months prior to the Screening (Day -7) visit or anticipated use of such procedures during the study 
2.03 Use of lid-heating therapy (ie, Lipi[INVESTIGATOR_69177]®, iLUX®, etc.), Meibomian gland probing, or 
therapeutic Meibomian gland expression in either eye < 6 months prior to the Screening visit (Day -7) or anticipated use during the study
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427350] history of ocular/ophthalmic surgery or trauma, which could affect corneal 
sensitivity and/or tear distribution (eg, cataract surgery, laser-assisted in situ 
keratomileusis [LASIK], photorefractive keratectomy, or any surgery involving a limbal or corneal incision) within 12 months prior to the Screening (Day -7) visit 
2.05Are currently using topi[INVESTIGATOR_94625] (OTC, herbal or prescription) or TrueTear®
(intranasal neurostimulator), or have used topi[INVESTIGATOR_94625] (OTC, herbal or prescription) or TrueTear within 1 month of the Screening (Day -7) visit or plan use ofsuch treatments during the study. Exception: participants who are using the following can be considered: 
!Marketed artificial tear product for the management of DED, which must be 
discontinued at the Screening (Day -7) visit
!Monotherapy for glaucoma or OHT using a prostaglandin analog, beta blocker, 
alpha-[ADDRESS_427351], or carbonic anhydrase inhibitor; any topi[INVESTIGATOR_15434]-lowering 
medications must have a start date of ≥ 90 days prior to the Screening (Day -7) visit 
and dosage is not expected to change during the study
!Cyclosporine topi[INVESTIGATOR_344336] (eg, RESTASIS or other ophthalmic form) or lifitegrast 5% ophthalmic solution (Xiidra), with a start date of ≥ 90 days 
prior to the Screening (Day -7) visit and dosage is not expected to change during the study
NOTE: Participants currently being treated with BOTH an IOP-lowering 
medication and topi[INVESTIGATOR_344337].
2.06 IOP > 21 mm Hg at the Screening (Day -7) visit in both eyes. Participants with primary
open-angle glaucoma or OHT may be included provided they are on stable monotherapy
bilaterally as mentioned in exclusion criterion 2.05, with both eyes IOP controlled ( ≤ 21 
mm Hg). The type of medication will be recorded at the Screening (Day -7) visit along with other concomitant medications
3. Prior/Concurrent Clinical Study Experience
3.01 Are currently enrollment in an investigational drug or device study or participation in 
such a study within 30 days of entry into this study at the Screening (Day -7) visit
4. Diagnostic Assessments
4.[ADDRESS_427352] (with anesthesia) ≤ 2 mm in either eye at the Screening (Day -7) 
visit
4.02 Report an average daily artificial tear use of > 6 times per day within 6 months of the 
Screening (Day -7) visit 
5. Other
Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427353]-T-01-01 v3.05.01 Females who are pregnant, nursing, or planning a pregnancy during the study orfemales 
who are of childbearing potential and not using a reliable method of contraception (see 
Appendix 6 )
5.[ADDRESS_427354] history of allergies or sensitivity to the study interventions or its components (including all REFRESH and Systane product lines) or diagnostics (eg, topi[INVESTIGATOR_50019], sodium fluorescein, or lissamine green)
5.[ADDRESS_427355] a condition or is in a situation which, in the investigator’s opi[INVESTIGATOR_1649], may put the 
participant at significant risk, may confound the study results, or may interfere 
significantly with the participant’s participation in the study
5.[ADDRESS_427356] and administration of this study as an 
investigator, subinvestigator, study coordinator or other study staff member; employee of Allergan or a first-degree family member, significant other or relative residing with one of the above persons involved directly or indirectly in the study; are enrolled in this studyat another clinical site; or, are a student with a direct relationship with the investigator or investigational site staff
5.3. Lifestyle Considerations
No restrictions are required.
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently entered in the study. A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatoryauthorities. Minimal information includes indicating screen failure as reason for ending the 
study, demography, screen failure details, eligibility criteria, and any serious adverse event 
(SAE).
Individuals who do not meet the criteria for participation in this study (screen failures) may be 
rescreened with sponsor pre-approval. 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427357]-T-01-01 v3.06. Study Intervention
Study intervention is defined as any investigational interventions intended to be administered to 
a study participant according to the study protocol.
6.1. Study Interventions Administered
The study interventions to be administered are as follows:
Study Intervention 
Name [CONTACT_344378] (011516X) Systane Ultra MD REFRESH PLUS (8197X)
Dosage Formulation Topi[INVESTIGATOR_344338], Waco, TX Alcon Allergan, Waco, TX
Identity of Formulation and 
StrengthsCarboxymethyl-cellulose 
sodium 0.5%
Glycerin 0.9% with 
trehalosePolyethylene glycol 400 
0.4%
Propylene glycol 0.3%Carboxymethyl-cellulose 
sodium 0.5%
Route of Administration Topi[INVESTIGATOR_344339] 1 to 2 drops in each 
eye, 3 times per dayInstill 1 to 2 drops in each 
eye, 3 times per dayInstill 1 to 2 drops in each 
eye, 3 times per day
Packaging and LabelingStudy intervention will be 
provided in unit-dose vials. 
Study intervention will be 
labeled as required.Study intervention will be 
provided in MD bottles. 
Study intervention will be 
labeled as required.Study intervention will be 
provided in unit-dose vials. 
Study intervention will be 
labeled as required.
Number and Timing of InterventionsParticipants will administer 
1 to 2 drops in each eye 3 
times dailyParticipants will 
administer 1 to 2 drops in 
each eye 3 times dailyParticipants will administer 
1 to 2 drops in each eye 
3 times daily
Volume Per 
Intervention Vial or 
Bottle0.4 mL vial 10 mL bottle 0.4 mL vial
As this is a single-masked study, 011516X and Systane Ultra MD will each be supplied in 
identical outer cartons (kit). Each kit label will include the study number, kit number, and a place for the site to write-in the participant’s study ID once assigned by [CONTACT_344354] (IxRS) to a particular participant.
6.1.1. Run-in Medications and Administration
The REFRESH PLUS solution (8197X) contains the following: CMC sodium, sodium 
hydroxide, sodium chloride, sodium lactate, potassium chloride, calcium chloride, magnesium 
chloride, and water for injection/purified water. The solution is supplied in 0.4 mL unit-dose
vials. The solution is sterile and isotonic.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427358]-T-01-01 v3.06.1.2. Study Supplies
The following supplies will be provided by [CONTACT_78562]:
!Urine pregnancy tests
!Distance logarithmic visual acuity chart for testing at 3 meters
!Stopwatch (for TBUT)
!2% preservative-free liquid sodium fluorescein (for TBUT and corneal staining)
!Micropi[INVESTIGATOR_344340] (for fluorescein administration)
!Yellow barrier filter (for TBUT and corneal staining with fluorescein)
!Lissamine green strips (for conjunctival staining)
!Saline (used to wet the lissamine green strips)
!Timer (for Schirmer test with anesthesia)
!Topi[INVESTIGATOR_15413] (for IOP measure and Schirmer test)
!Schirmer strips (for Schirmer test with anesthesia)
!Visual analog scale ruler (for converting the participant’s V AS responses to numerical 
values)
The following will be provided by [CONTACT_093]:
!Slit-lamp biomicroscope
!Goldmann applanation tonometer 
!Internet connection (high-speed connection for electronic case report form [eCRF]completion)
!Temperature monitoring device for study intervention storage
6.1.3. Instructions for Use and Administration
At Screening (Day -7), run-in medication (REFRESH PLUS) will be dispensed to each eligible
participant. Each participant will be instructed to instill 1 to 2 drops in each eye, 3 times per day. 
The same vial can be used for both eyes, and should be used 1 time only. The used and unused 
vials should be collected and returned to the sites for accountability as instructed.
Assigned study intervention will be dispensed to each randomized participant at the Days 1, 30, 
and 60 by [CONTACT_344355]. Participants randomized to the NATF unit-dose formulation 
(011516X) will be instructed to instill 1 to 2 drops in each eye, 3 times per day. The same vial 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427359]-T-01-01 v3.0can be used for both eyes, and should be used 1 time only. The used and unused vials should be 
collected and returned to the site for accountability as instructed. Participants randomized to 
Systane Ultra MD (10 mL bottles) are to use [ADDRESS_427360] 5% 
ophthalmic solution (Xiidra) or glaucoma therapy drops as allowed per inclusion/exclusion criteria during the study, the participant should be instructed to wait a minimum of 15 minutes 
between drop instillations (with study intervention being administered first). In addition, 
participants should be instructed to not use study intervention within 4 hours of each 
follow-up visit (ie, Days 7, 30, 60, and 90/Early Exit).
6.2. Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.
2. Only participants enrolled in the study may receive study intervention, and only
authorized site staff may supply or administer study intervention. All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access limited to 
the investigator and authorized site staff.
3. Participants will be instructed on the proper storage of study intervention and to keep it 
out of the reach of children at all times.
4. Acceptance of the returned used and unused vials and used and unused bottles should be 
handled by [CONTACT_344355]. However, the investigator, institution, or the head of 
the medical institution (where applicable) is ultimately responsible for study intervention 
accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).
5. At the end of the study, all used and unused study intervention will be reconciled and used 
and unused vials and bottles must be returned to Allergan.
6.3. Measures to Minimize Bias: Randomization and Masking
This study will use a 1:1 treatment allocation to 011516X:Systane Ultra MD, with a central stratification by [CONTACT_2006] 1 (Baseline) total ocular staining score in the study eye (mild/moderate = 
score of 6 to 25 vs severe = score of 26 to 43). The study eye is defined as the worst eye based on 
total ocular staining score at Day 1 (Baseline). If both eyes have the same total ocular staining 
score, the right eye will be designated as the study eye.
Prior to initiation of study intervention, each participant who provides informed consent will be 
assigned to a participant number through an automated IxRS that will serve as the participant’sidentification number on all study documents. Participant numbers will be assigned in ascending order across all sites and should not be omitted or reused.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427361]-T-01-01 v3.0At the end of the Screening (Day -7) visit, all eligible participants will receive a run-in
medication kit (REFRESH PLUS) for use during the 7-day run-in period. Sites will dispense the 
run-in medication kit according to the IxRS instructions. 
At the end of the Day 1 (Baseline) visit, all eligible participants will be stratified by [CONTACT_344356] 1 
(Baseline) study eye total ocular staining score and be randomly assigned to 1 of 2 treatment 
arms in a 1:1 ratio based on a randomization scheme prepared by [CONTACT_344357]. This will require the delegated site personnel to enter the participant’s Screening Visit (Day -7) and 
Baseline (Day 1) total corneal and conjunctival staining scores of each eye directly into IxRS. 
IxRs will then determine which eye is the study eye and assign the participant to a stratification group and a treatment arm, thus providing the site with the specific study intervention kit assignment. Sites will dispense study intervention according to the IxRS instructions.
Sites will also need to access the IxRS at the Days 30 and 60 visits to obtain a study intervention
kit (30-day supply) number to dispense to the participant. Sites will receive the IxRS 
confirmation notifications for each transaction. All notifications are to be maintained with the 
study source documents.
In addition, sites will need to access IxRS to “complete” the participant at Day 90 or to 
“discontinue” the participant if they exit the study early.
6.4. Study Intervention Compliance
When the participants are dispensed their inte rvention kits (Days 1 [Baseline], 30, and 60), they
will be instructed to use 1 to 2 drops in each eye, 3 times per day.
Study intervention compliance will be monitored by: 1) having the participants complete the 
Study Eye Drop Usage Questionnaire at Day 1 (Baseline) and at each follow-up visit, and 2) having the participants return both their used and unused vials for those participants stratified to 
the NATF formulation and both their used and unused bottles for those participants stratified to 
Systane Ultra MD.
The used and unused vials and bottles will be returned at each participant’s Day 30, Day 60, and 
Day 90/Early Exit Visits and the study site’s impartial dispenser will keep an accurate record of 
what is dispensed and returned for each participant throughout the study.
6.5. Concomitant Therapy
The use of any new concomitant medication, prescription or OTC, is to be recorded on the participant’s source document at each visit along with the reason the medication is being taken.
At Screening (Day -7), Baseline (Day 1), and at each follow-up visit, study staff will question 
each participant specifically on the use of concomitant medications. Whenever possible, studystaff should notify Allergan immediately if a participant uses any concomitant medications not 
permitted by [CONTACT_760]. Participants who used prohibited concomitant medications (see 
Section 6.5.3 ), will be discontinued from the study and early termination procedures pertaining 
to safety assessments are recommended to be followed (see Section 1.3 ).
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427362]-T-01-01 v3.06.5.1. Prohibited Treatments and Washout Before the Study
Any systemic medication (including OTC, herbal, prescription, or nutritional supplements) that 
may affect DED or vision should be stably used for at least 90 days prior to the Screening 
(Day -7) visit. Systemic medications, which may affect DED or vision, include but are not limited to the following: flax seed oil, fish oil, omega-[ADDRESS_427363] lens use is prohibited 90 days prior to the screening (Day -7) visit. Participants are not 
allowed to have any scheduled or planned ocular or systemic surgery or procedure during the 
study that, in the investigator’s opi[INVESTIGATOR_1649], may inhibit the participant’s study participation. Participants are not allowed to receive temporary or permanent occlusion or cauterization of the lacrimal puncta < 6 months prior to the Screening (Day -7) visit.
Participants should not have ocular/ophthalmic surgery or trauma, which could affect corneal 
sensitivity and/or tear distribution (eg, cataract surgery, LASIK, photorefractive keratectomy, or 
any surgery involving a limbal or corneal incision) within 12 months prior to the Screening 
(Day -7) visit.
Participants should not use lid-heating therapy (ie, Lipi[INVESTIGATOR_69177], iLUX, etc.), Meibomian gland 
probing, or therapeutic Meibomian gland expression in either eye within 6 months prior to the 
Screening (Day -7) visit.
Participants should not use TrueTear or other topi[INVESTIGATOR_213726] (OTC or prescription), 
except the monotherapy for glaucoma or OHT, or cyclosporine topi[INVESTIGATOR_344336] 
(eg, RESTASIS or other ophthalmic form) or lifitegrast 5% ophthalmic solution (Xiidra) within 1 month of the Screening (Day -7) visit.
Lastly, nonstudy artificial tear products can only be used before the Screening (Day -7) visit and 
cannot be used for the remainder of the study.
6.5.2. Permitted Treatments
Therapy considered necessary for the participant's welfare may be given at the discretion of the 
investigator. Systemic medications that do not cause or affect DED, dry mouth, changes in 
vision (as per exclusion criterion 2.01) or other ocular changes are considered permissible 
medications. Use of artificial tear products will be limited to only REFRESH PLUS during the 
run-in period. Thereafter, use of any artificial tear product, except the assigned study
intervention, is prohibited for the duration of the study. Topi[INVESTIGATOR_344341], except for participants meeting all inclusion and exclusion criteria for 
their use of monotherapy for glaucoma or OHT, or use of a cyclosporine topi[INVESTIGATOR_344342] (eg, RESTASIS or other ophthalmic form) or lifitegrast 5% ophthalmic solution (Xiidra). Participants using any of these products, should continue to use their drops at the same 
dose and frequency for the duration of the study. If the permissibility of a specific 
medication/treatment is in question, please contact [CONTACT_78562].
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427364]-T-01-01 v3.0Any medication or vaccine (including OTC or prescription medicines, vitamins, and/or herbal 
supplements) that the participant is receiving at the time of enrollment or receives during the 
study must be recorded along with the following:
!Indication
!Dates of administration including start and end dates
!Dosage information including route, dose and frequency
Therapy considered necessary for the participant’s welfare may be given at the discretion of the investigator. If the permissibility of a specific medication/intervention is in question, please contact [CONTACT_78562].
Allergan should be contact[CONTACT_344358].
Any medication taken during the study between the date of the first dose (Day 1 [Baseline]) of 
study intervention and the date of the study exit will be recorded on the source document as a 
concomitant medication; any medication started after the study exit will not be considered a concomitant medication and should not be captured in the eCRF.
6.5.3. Prohibited Treatments During the Study
!Participants are not allowed to have any scheduled or planned ocular or systemic surgery or 
procedure during the study that, in the investigator’s opi[INVESTIGATOR_1649], may inhibit the participant’s study participation.
!Participants are not allowed to receive temporary or permanent occlusion or cauterization of the lacrimal puncta during the study.
!After Screening (Day -7), participants should not begin or stop the use of or change dose on any systemic medications (OTC, herbal, prescription, or nutritional supplements) that mayaffect a dry eye condition or affect vision (eg, may cause blurred vision, cataracts, or 
glaucoma). Sites should look up the potential adverse reactions of each medication to 
ensure they do not fall within these exclusionary drug families . The following exceptions 
are applicable after the Screening Visit (Day -7) for participants that initiate the following to facilitate short-term treatment of systemic conditions such as allergies, cold/flu, and 
pain/headache:
oUse of systemic antihistamines for up to 7 consecutive days 
oUse of cold/flu medications used for up to 7consecutive days
oUse of over-the-counter pain medications (aspi[INVESTIGATOR_248], acetaminophen, etc.) for up 
to 7consecutive days
!Participants should not use any lid-heating therapy (ie, Lipi[INVESTIGATOR_69177], iLUX, etc.), Meibomian 
gland probing, or therapeutic Meibomian gland expression in either eye during the study.
!Participants should not begin or stop any topi[INVESTIGATOR_78521].
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427365]-T-01-01 v3.0!Participants should not change dose on allowable topi[INVESTIGATOR_344343]/exclusion criteria (monotherapy for glaucoma or OHT, cyclosporine topi[INVESTIGATOR_344336] (eg, RESTASIS or other ophthalmic form) or lifitegrast 5% 
ophthalmic solution (Xiidra) while enrolled in the study.
!Participants may not use any artificial tear product, except the run-in medication (during the 
screening period) and the assigned study intervention (after randomization).
!The decision to administer a prohibited medication/treatment is done with the safety of the study participant as the primary consideration. When possible, Allergan should be notified 
before the prohibited medication/treatment is administered.
6.5.4. Rescue Medicine
Rescue medicine is not applicable.
6.6. Dose Modification
Dose modification is not applicable.
6.7. Intervention after the End of the Study
No interventions after the end of the study are planned.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427366]-T-01-01 v3.07. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
A premature discontinuation will occur if a participant, who signs the ICF and is dosed, ceases 
participation in the study and the completion of the protocol-defined study procedures and visits, 
regardless of the circumstances.
Reasons for discontinuation from the study treatment and/or the study may include the following 
commonly used or other acceptable terms:
Commonly Used Terms Other Acceptable Terms
AE Death
Lack of efficacy
Lost to follow-up
Noncompliance with study intervention
Other
Physician decision
Pregnancy
Protocol deviation
Screen failure
Site terminated by [CONTACT_344359]
7.1. Discontinuation of Study Intervention
See the SoA (Section 1.3 ) for data to be collected at the time of early exit.
7.2. Participant Discontinuation/Withdrawal from the Study
!A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons.
!Participants will be discontinued if they use any prohibited treatments described in Section 6.5.3 of this protocol.
!For participants who discontinue the study early, every effort should be made to have these participants return to the clinical center for completion of the early exit visit. 
Adverse events leading to a participant’s early discontinuation must be followed up as 
appropriate.
!If the participant withdraws consent for disclosure of future information, Allergan may retain and continue to use any data collected before such a withdrawal of consent.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427367]-T-01-01 v3.0!See the SoA (Section 1.3 ) for data to be collected at the time of study discontinuation and 
follow-up and for any further evaluations that need to be completed. 
7.3. Lost to Follow-Up
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].
The following actions must be taken if a participant fails to return to the study site for a required 
study visit:
!The site must attempt to contact [CONTACT_344360]/or should continue in the 
study.
!Before a participant is deemed lost to follow-up, the investigator or designee must make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls, and if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_9145]’s 
source document.
!Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.
!Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1.
8. Study Assessments and Procedures
!Study procedures and their timing are summarized in the SoA (Section 1.3). Protocol 
waivers or exemptions are not allowed.
!Any safety concerns should be discussed with Allergan immediately upon occurrence or 
awareness to determine whether the participant should continue or discontinue study
intervention.
!Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.
!All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screen failure, as applicable.
Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427368]-T-01-01 v3.08.1. Efficacy Assessments
Efficacy assessments include the following: corneal staining, conjunctival staining, Schirmer test 
(with anesthesia), OSDI score, TBUT, and self-assessed questionnaires/surveys.
Timing and measurement details are provided in Table 8-1 .
Table 8-1 Efficacy Assessments
Assessment Timing Measurement
Primary Efficacy Measure
Total staining !Screening and Days 1, 7, 30, 
60, and 90/Early Exit!Total staining score will be the sum of corneal and conjunctival staining score.
Secondary Efficacy Measure
Current Symptom Survey!Screening and Days 1, 7, 30, 60, and 90/Early Exit!A self-assessed 6-item visual analog scale (VAS) survey that assesses various symptoms of DED disease.
Other Efficacy Measures
Corneal Staining (modified NEI 
grading scheme, 
with fluorescein)!Screening and Days 1, 7, 30, 60, and 90/Early Exit!Corneal staining will be assessed in each eye after the evaluation of TBUT, using the modified NEI grading scheme).
Conjunctival staining (Modified 
NEI grading 
scheme, with lissamine green)!Screening and Days 1, 7, 30, 60, and 90/Early Exit!Conjunctival staining will be assessed in each eyeusing the modified NEI grading scheme
Schirmer test (with 
anaesthesia)!Screening and Days 1, 7, 30, 60, and 90/Early Exit!Schirmer test with anesthesia will be performed in each eye after all other ophthalmic testing.
TBUT (with 
fluorescein)!Screening and Days 1, 7, 30, 60, and 90/Early Exit!TBUT is the time in seconds required for dry spots to appear on the corneal surface after blinking.
OSDI Questionnaire Score!Screening and Days 1, 7, 30, 60, and 90/Early Exit!Participants will be asked to evaluate the frequency of various symptoms, related visual functions, and environmental triggers of DED using a 5-point scale. This is a self-assessed overall evaluation, not per eye.
Study Eye Drop Experience and Tolerability Questionnaire!Days 7, 30, 60, and 90/Early Exit!A self-assessed survey that evaluates the immediate, short- and long-term participant experience in comfort and vision with the study intervention, as 
well as tolerability of the assigned study intervention
over the past week in selected performance measures, using a VAS.
Functional Vision 
Questionnaire!Days 1, 7, 30, 60, and 90/Early Exit!A self-assessed questionnaire to assess visual function within the past 3 days.
5-Minute Blurry 
Vision and Ocular Discomfort Questionnaire!Days 1 and 90/Early Exit !A 2-question VAS survey evaluates the participant’s blurry vision and ocular discomfort before dosing and at 30 seconds, 1 minute, 90 seconds, and 2, 3, 4, and 5 minutes after dosing.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427369]-T-01-01 v3.08.1.1. Primary Efficacy Assessment
[IP_ADDRESS]. Total Staining
Total staining score will be determined as the sum of corneal and conjunctival staining scores.
8.1.2. Secondary Efficacy Assessment
[IP_ADDRESS]. Current Symptom Survey
At all visits, the Current Symptom Survey will be completed by [CONTACT_344361] [ADDRESS_427370] 24 hours, except the few minutes immediately after using eye drops. A trained member of the study
personnel will then use the provided VAS ruler to convert the participant’s response to a 
numerical value (0 to 100). This is an overall evaluation, not per eye. The questionnaire will read as follows ( Note: The VAS scales will be an actual scale and not just text as indicated below for 
the purposes of this protocol): 
Think about how your eyes have felt over the past [ADDRESS_427371] 24 hours:
1. Burning (VAS anchors: 0 = no burning, 100 = maximum burning)
2. Dryness (VAS anchors: 0 = no dryness, 100 = maximum dryness)3. Irritation (V AS anchors: 0 = no irritation, 100 = maximum irritation)
4. Grittiness/foreign body sensation (V AS anchors: 0 = no grittiness/foreign body sensation, 
100 = maximum grittiness/foreign body sensation)
5. Blurry/fluctuating vision (V AS anchors: 0 = no blurry/fluctuating vision, 100 = maximum 
blurry/fluctuating vision)
6. Overall ocular pain/discomfort (V AS anchors: 0 = no pain/discomfort, 100 = maximum 
pain/discomfort)
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427372]-T-01-01 v3.08.1.3. Other Efficacy Assessments
[IP_ADDRESS]. Tear Break-up Time (with Fluorescein)
TBUT will be performed on both eyes at all visits. 
Slit-lamp settings should be adjusted to a magnification of 10X to 16X using a cobalt blue filter 
and yellow barrier filter placed directly in front of the objective lens of the slit-lamp. The 
slit-lamp’s light source must be set to high intensity (increased voltage) when the cobalt blue and 
enhancement filters are in place.
Participants will be asked to tilt their heads slightly back and, starting with the right eye, 5 μL of 
2% preservative-free liquid sodium fluorescein will be applied to the lower cul-de-sac using a 
micropi[INVESTIGATOR_344344]. To thoroughly mix the fluorescein with the tear film, the participant will be instructed to blink several times over approximately [ADDRESS_427373] blink until 1 or more black (dry) spots appear in the precorneal tear film (not just local thinning or tear film 
irregularity). After the first measurement, the participant will be instructed to blink naturally
[ADDRESS_427374] tenth of a second. 
[IP_ADDRESS]. Corneal Staining (Modified NEI Grading Scheme, with Fluorescein)
Corneal staining will be evaluated in each eye at all visits.
Approximately 3 minutes after instillation of sodium fluorescein and subsequent assessment of 
TBUT in both eyes (see Section [IP_ADDRESS]), the cornea will be evaluated for staining, starting with 
the right eye. No additional liquid sodium fluorescein should be instilled.
Fluorescein staining will be evaluated using a slit-lamp with full slit width and approximately
10X to 16X magnification with cobalt blue illumination and a yellow barrier filter to enhance contrast. The yellow barrier filter must be placed directly in front of the objective lens of the slit-
lamp. The slit-lamp’s light source should also be set to high intensity (increased voltage) when the cobalt blue and enhancement filters are in place. 
Grading of the resulting corneal staining will be based on the Modified NEI (National Eye 
Institute/Industry Workshop) grading scheme ( Lemp 1995, Pflugfelder 2008 ). The schematic 
representations of the 5 corneal regions per eye are shown in Figure 8-1 . Each of the 5 areas on 
the cornea of each eye is to be graded independently (0-5 per region). The upper eyelid is lifted slightly to grade the entire corneal surface. This procedure should then be repeated in the left 
eye. The total corneal staining score is calculated as the sum of grading score of 5 regions. The maximum possible score for total corneal staining is 25.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427375]-T-01-01 v3.0Figure 8-1 Modified NEI Grading Scheme Part 1: Corneal Staining Grading Scheme
Grade each zone using the dot count scale:
Dot Count Grade
No staining 0
1 to 5 dots 1
6 to 15 dots 2
16 to 30 dots 3
> 30 dots 4
> 30 dots + confluence 5
[IP_ADDRESS]. Conjunctival Staining (Modified NEI Grading Scheme, with Lissamine Green)
Interpalpebral conjunctival staining will be graded following the corneal staining evaluation at 
all visits starting with the right eye. 
With the sterile lissamine green strip still in the package, the impregnated side of the strip should 
be grasped, and the outer package torn in half vertically, exposing the white portion of the strip. 
Graspi[INVESTIGATOR_344345], the impregnated side of the strip should be moistened with 2 drops of sterile saline solution, allowing the solution to pool into a droplet at the end of 
the strip. The participant should then be instructed to look up such that 1 drop of lissamine green 
can be applied to the right eye by [CONTACT_344362], releasing the droplet. Ensure not to touch the paper strip to bulbar 
conjunctiva. A second (new) lissamine green strip will then be immediately wetted with 2 drops 
of sterile saline solution such that a drop of lissamine green can be added to the left eye. To thoroughly mix the lissamine green with the tear film, the participant will be instructed to blink 
several times over approximately 15 seconds. Approximately 1 minute after instillation and 
starting with the right eye, grading of the resulting corneal staining will be based on the Modified NEI (National Eye Institute/Industry Workshop) grading scale. 
Using the white light of low to moderate intensity, the 6 conjunctival regions (3 nasal and 
3 temporal) will be graded using the modified NEI grading scheme (score between 0 and 5 per region) yielding a maximum possible score per eye of 30. The schematic representation of the 
6 conjunctival regions per eye is shown in Figure 8-2 . To grade the temporal zone, the 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427376]-T-01-01 v3.0participant should be instructed to look nasally; to grade the nasal zone, the participant should be 
instructed to look temporally. 
Figure 8-2 Modified NEI Grading Scheme Part 2: Conjunctival Staining Grading Scheme
Grade each zone using the dot count scale:
Dot Count Grade
No staining 0
1 to 5 dots 1
6 to 15 dots 2
16 to 30 dots 3
> 30 dots 4
> 30 dots + confluence 5
[IP_ADDRESS]. Schirmer Test (with Anesthesia)
The Schirmer test (with anesthesia) should be performed in each eye after completion of both 
corneal and conjunctival staining at each study visit. 
One drop of anesthetic will be instilled into each eye. The participant will be instructed to keep 
the eyes gently closed for [ADDRESS_427377], a stopwatch (timer) should be started. To minimize artifacts from this 
test, participants should gently close their eyelids until [ADDRESS_427378] is to be conducted in a dimly lit room.
Strip Measuring: Write the letter “R” on the strip used in the OD (right) eye and the letter “L” on 
the strip used in the OS (left) eye. Each strip has graduated sections on it that will aid in 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427379] 
whole number if the tear front is at or greater than the half millimeter mark.
[IP_ADDRESS]. Ocular Surface Disease Index Questionnaire
At all visits, participants will complete an OSDI Questionnaire (see  next page ). The purpose of 
this assessment is to capture a range of ocular surface symptoms, including symptoms related to 
dry eye, their severity, and their impact on the participant’s ability to function, scaled into a 0 (no 
disease) to 100 (maximum severity of disease) score. The OSDI score is calculated as follows:
OSDI = (sum of scores) × 25/(number of questions answered)
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427380]-T-01-01 v3.0OCULAR SURFACE DISEASE INDEX©(OSDI) – To be completed by [CONTACT_344363].
Have you experienced any of the following during the last 
week?All of 
the 
TimeMost 
of the 
TimeHalf 
of the 
TimeSome 
of the 
TimeNone 
of the 
Time
1. Eyes that are sensitive to light?
2. Eyes that feel gritty?
3. Painful or sore eyes?
4. Blurred vision?
5. Poor vision?
Have problems with your eyes limited you in performing 
any of the following during the last week ?All of 
the 
TimeMost 
of the 
TimeHalf 
of the 
TimeSome 
of the 
TimeNone 
of the 
TimeN/A
6. Reading?
7. Driving at night?
8. Working with a computer or bank machine 
(ATM)?
9. Watching TV?
Have your eyes felt uncomfortable in any of the following situations during the last week ?All
of the 
TimeMost 
of the 
TimeHalf 
of the 
TimeSome 
of the 
TimeNone 
of the 
TimeN/A
10. Windy conditions?
11. Places or areas with low humidity (very dry)?
12. Areas that are air-conditioned?
Participant Signature: _____________________               
                                                                              Day              Month               Year  
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427381]-T-01-01 v3.[IP_ADDRESS]. Study Eye Drop Experience and Tolerability Questionnaire
This questionnaire evaluates the short- and long-term subjective experience in comfort and 
vision with the study eye drops, as well as the tolerability of the assigned study eye drops over 
the past week, using a VAS. At Day 1 (Baseline) and all follow-up visits, the Study Eye Drop Experience and Tolerability Survey will be completed by [CONTACT_20908]. Participants should be 
instructed to mark a vertical line on the anchored VAS that best describes their agreement with 
the statements within the questionnaire. A trained member of the study site personnel will then use the provided VAS ruler to convert the participant’s response to a numerical value (0 to 100). 
This is an overall evaluation, not per eye. The questionnaire will read as follows ( Note: The 
VAS scales will be actual scales and not just text as indicated below for the purposes of this 
protocol.):
Think about your experience with the study eye drops within the first [ADDRESS_427382] describes your agreement with the following statements:
1. The study eye drops do not cause stinging or burning in my eyes. (V AS anchors: 
0 = strongly disagree, 100 = strongly agree)
2. The study eye drops provided immediate relief of my eye dryness. (V AS anchors: 
0 = strongly disagree, 100 = strongly agree)
Now think about your experience with the study eye drops [ADDRESS_427383] describes your agreement with the following statements:
3. The study eye drops are very soothing for my eyes. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
4. The study eye drops did not feel sticky. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
5. The study eye drops continued to provide relief of my eye dryness. (V AS anchors: 
0 = strongly disagree, 100 = strongly agree)
Lastly, think about how you have felt over the last week while using the study eye drops. Using the scales provided below, please mark a vertical line at the place that best describes your agreement with the following statements:
6. The study eye drops provided long-lasting relief of my eye dryness. (V AS anchors: 
0 = strongly disagree, 100 = strongly agree) 
[IP_ADDRESS]. Functional Vision Questionnaire
This questionnaire evaluates the functional vision as a consequence of using the study eye drops 
over the past 3 days in selected performance measures using a VAS. At Day 1 (Baseline) and all 
follow-up visits, the Functional Vision Questionnaire should be completed by [CONTACT_344364]. All measurements will be done on an anchored VAS. Participants should be instructed to mark a 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427384] describes their agreement with the statements within 
the questionnaire. A trained member of the study personnel will then use the provided ruler to 
convert the participant’s response to a numerical value (0 to 100). This is an overall evaluation, not per eye. Participants will be asked 19 questions. The questionnaire will read as follows 
(Note: The VAS scales will be actual scales and not just text as indicated below for the purposes 
of this protocol):
Think about your vision over the past 3 days. You will be asked several questions about your 
general vision, then questions on specific activities such as watching television (TV), using a 
computer, using a cell phone and reading a book or magazine. If a particular question does not apply to you, you may check N/A (not applicable) where specified. Using the scales 
provided below, please mark a vertical line at the place that best describes your agreement with 
the following statements:
GENERAL VISION – Over the past 3 days:
1. My vision was blurry. (VAS anchors: 0 = strongly disagree, 100 = strongly agree)
2. I needed to blink frequently because of blurry vision. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
3. My eyes got tired because of blurry vision. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
WATCHING TV – Over the past 3 days:
4. I have clear vision when watching TV . (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
5. I can watch TV for as long as I would like. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
6. I never stop watching TV due to blurry vision. (V AS anchors: 0 = strongly disagree, 100 = 
strongly agree)
7. I enjoy watching TV more as I have less blurry vision. (V AS anchors: 0 = strongly 
disagree, 100 = strongly agree)
USING A COMPUTER – Over the past 3 days:
8. I have clear vision when looking at my computer screen. (V AS anchors: 0 = strongly 
disagree, 100 = strongly agree)
9. I can read the computer screen as fast as I would like. (V AS anchors: 0 = strongly 
disagree, 100 = strongly agree)
10. I can use my computer for as long as I would like. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
11. I never stop using my computer due to blurry vision. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427385]-T-01-01 v3.0USING A CELL PHONE – Over the past 3 days:
12. I have clear vision when looking at my cell phone. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
13. I never have a problem using my cell phone due to blurry vision. (V AS anchors: 
0 = strongly disagree, 100 = strongly agree)
14. I can use my cell phone more as I have less blurry vision. (V AS anchors: 0 = strongly 
disagree, 100 = strongly agree)
READING A BOOK OR MAGAZINE – Over the past 3 days:
15. I have clear vision when reading. (V AS anchors: 0 = strongly disagree, 100 = strongly 
agree)
16. I can read as fast as I would like. (V AS anchors: 0 = strongly disagree, 100 = strongly 
agree)
17. I can read for as long as I would like. (V AS anchors: 0 = strongly disagree, 100 = strongly 
agree)
18. I never stop reading due to blurry vision. (VAS anchors: 0 = strongly disagree, 
100 = strongly agree)
19. I enjoy reading more as I have less blurry vision. (V AS anchors: 0 = strongly disagree, 
100 = strongly agree)
[IP_ADDRESS]. 5-Minute Blurry Vision and Ocular Discomfort Questionnaire
The 5-Minute Blurry Vision and Ocular Discomfort Questionnaire will be used to assess the 
degree of the participant’s blurry vision and ocular discomfort. The questionnaire will be 
completed by [CONTACT_344365] 1 (Baseline) and Day 90/Early Exit before the studyeye drop instillation and at [ADDRESS_427386] describes the amount of blurry vision, respective ocular discomfort they are 
experiencing at each timepoint. A trained member of the study site personnel will then use the 
provided VAS ruler to convert the participant’s response to a numerical value (0 to 100). This is an overall evaluation, not per eye. The questionnaire will read as follows ( Note: The VAS scales 
will be an actual scale and not just text as indicated below for the purposes of this protocol.): 
Using the 2 sets of scales below, you will be asked to rate the amount of blurry vision and 
ocular discomfort you are experiencing before the instillation and over the 5 minutes immediately after instillation of the study eye drop.
The amount of blurry vision you are experiencing can range from “No Blurry Vision” (Score 
of 0) to “Extreme Blurry Vision” (Score of 100) and this may change over the 5 minutes you are rating.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427387]-T-01-01 v3.0The amount of ocular discomfort you are experiencing can range from “No Ocular 
Discomfort” (Score of 0) to “Extreme Ocular Discomfort” (Score of 100) and this may change 
over the 5 minutes you are rating.
8.2. Safety Assessments
Planned timepoints for all safety assessments are provided in the SoA.
8.2.1. Currently Corrected Distance Visual Acuity
At all visits, corrected visual acuity will be measured using a logarithmic visual acuity chart with 
Sloan letters for testing at 3 meters (9 feet, 10 inches). One chart is provided with right, left, and center acuity targets, and will be used as described below. Make sure the participant is tested 
using his/her current distance correction, if applicable. (Note: Participants should use the same 
distance correction, if required, at each visit, whenever possible). To provide standardized 
assessments of visual acuity during the study, all visual acuity assessments should be consistently carried out using the same lighting conditions during the entire study. Note: Test under normal 
office-like lighting conditions such that the chart is evenly lit without glare. Attach the chart to 
the wall at approximately eye level to the average height of a seated participant. Mark a spot on 
the floor (eg, with tape) that is 3 meters from the chart. Using this mark as a reference, position 
the participant so his/her eyes are [ADDRESS_427388] testing the right eye. Occlude the left eye. The participant should be asked to start 
on the top line of the bottom right chart (20/50 equivalent). Participants should be told to read the 
letters from left to right on each line and that the chart has letters only, no numbers. If the participant reads a number, he/she should be reminded that the chart contains no numbers, and 
the examiner should then request a letter in lieu of the number. The participant should be asked 
to read slowly so as to achieve best identification of each letter and not to proceed to the next letter until he/she has given a definite answer.
If the participant changes a response (eg, “that was a C not an O”) before he/she has read aloud 
the next letter, then the change must be accepted. If the participant changes a response after having read the next letter, then the change will not be accepted. The examiner must not point to specific letters during the test.
When the letters become difficult to read, or if the participant identifies a letter as one of 
2 letters, he/she should be asked to choose one letter and, if necessary, to guess. Participants 
should be encouraged to continue trying even when letters become difficult to read. Stop testing 
when 3 or more errors are made on the same line. Use the supplied source document worksheet to mark the letters missed for each line and to enter the number of letters correctly read for each 
line.
If a participant cannot read the 20/[ADDRESS_427389]. If the participant is still unable to read the 20/[ADDRESS_427390] him/her read from the top of the full center chart, letter by [CONTACT_31711], and record the number of 
letters missed and the number of letters correctly read for each line in the source document. 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427391] the participant start 
on the top line of the bottom left chart (20/50 equivalent). This strategy minimizes letter 
memorization.
8.2.2. Best-Corrected Distance Visual Acuity 
Best-corrected visual acuity will be measured at Day -7 (Screening) and Day 90/Early Exit visits 
using the same logarithmic visual acuity chart with Sloan letters for testing at 3 meters (9 feet, 
10 inches) that will be used for the currently corrected distance visual acuity. The LogMar chart will be viewed using a trial frame holding the best-corrected distance endpoint manifest 
refraction. (Measuring acuity using the phoropter is acceptable so long as the chart distance is 
3 meters.)
Sphere, cylinder, and axis will be determined and a consistent endpoint should be used, which is 
generally the least minus sphere that provides the participant's best measured acuity. Visual 
acuity should be determined using the same procedure used for currently corrected distance visual acuity. The phoropter may be either a plus or minus cylinder design. Values generated should be recorded directly from the phoropter without conversion.
Whenever possible, the same individual should perform the refraction and the same examination 
lane should be used.
8.2.3. Slit-Lamp Biomicroscopy 
Slit-lamp biomicroscopy ( without pupil dilation) will be performed on both eyes at all visits 
during the study. Observations for the slit-lamp biomicroscopy examination will be graded as 
described below. Findings other than those listed below should be recorded under “other” for the appropriate location of the finding.
The following will be examined at each visit:
!Eyelid/eyelid margins/lashes
!Conjunctiva 
!Cornea
!Anterior Chamber
EYELID / EYELID MARGINS / LASHES
Erythema
0 (None) No erythema
+ 0.5 (Trace) Localized, minimal (trace) flush reddish color
+ 1 (Mild) Localized, mild, flush reddish color
+ 2 (Moderate) Diffuse reddish color encompassing the entire lid margin+ 3 (Severe) Deep diffuse reddish color of lid margins and superior and/or 
inferior eyelid
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427392]-T-01-01 v3.0Edema (eyelids)
0 (None) No edema
+ 0.5 (Trace) Localized, minimal (trace) swelling
+ 1 (Mild) Localized, mild swelling
+ 2 (Moderate) Diffuse, moderate swelling+ 3 (Severe) Diffuse, severe swelling
CONJUNCTIVA (BULBAR AND PALPEBRAL)
Hyperemia
0 (None) No hyperemia
+ 0.5 (Trace) Minimal (trace) flush, reddish color 
+ 1 (Mild) Mild flush, reddish color + 2 (Moderate) Bright red color+ 3 (Severe) Deep, bright diffuse redness
Edema
0 (None) No edema
+ 0.5 (Trace) Localized, minimal (trace) swelling
+ 1 (Mild) Localized, mild swelling+ 2 (Moderate) Diffuse, moderate swelling + 3 (Severe) Diffuse, severe swelling
CORNEA
Edema
0 (None) No edema 
+ 0.5 (Trace) Localized, minimal (trace) epi[INVESTIGATOR_42247]
+ 1 (Mild) Dull glass appearance of epi[INVESTIGATOR_344346]
+ 2 (Moderate) Dull glass appearance of epi[INVESTIGATOR_344347]
+ 3 (Severe) Epi[INVESTIGATOR_101069]/or stromal edema, localized or diffuse, with 
or without stromal striae
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427393]-T-01-01 v3.0ANTERIOR CHAMBER
For the measurements of cells and flare based on standardized uveitis nomenclature, the 
following settings should be used:
!1 × 1 mm slit !High magnification
!Highest slit-lamp voltage !Low ambient lighting
!Illumination angle of 45 degrees !Same grader and slit-lamp whenever possible
Cells
0 = 0 cells 
+ 0.5 = 1 to 5 cells (trace) 
+ 1 = 6 to 15 cells
+ 2 = 16 to 25 cells+ 3 = 26 to 50 cells
+ 4 = > 50 cells
Flare
0 = None: no flare seen
+ 1 = Faint: faint flare seen+ 2 = Moderate: iris and lens details clear
+ 3 = Marked: iris and lens details hazy
+ 4 = Intense: fibrin or plastic aqueous
8.2.4. Urine Pregnancy Test
Women of childbearing potential will have urine pregnancy tests performed at the Screening 
(Day -7) and Day 90/Early Exit visits. At each visit, the investigator should discuss contraceptive use compliance with WOCBP. Additional details are provided in Appendix 6 .
8.2.5. Intraocular Pressure (with Anesthesia and Fluorescein)
After the Schirmer test with anesthetic is administered, IOP will be measured for each eye at 
Screening (Day -7) and Baseline (Day 1) and at all follow-up visits for participants with 
glaucoma or OHT only. Measurements should be taken using a Goldmann applanation tonometer affixed to a slit-lamp with the participant seated. Additional sodium fluorescein can be applied if needed. The participant and slit-lamp should be adjusted so that the participant’s head is firmly 
positioned on the chin rest and against the forehead rest without leaning forward or straining. 
Tight-fitting neckwear should be loosened. Both eyes will be tested, with the right eye preceding the left eye. The measurer looks through the binocular viewer of the slit lamp at low power. The 
tension knob is preset at a low pressure value (4 to 6 mm Hg). The measurer follows the image 
of the fluorescein-stained semicircles while he/she slowly rotates the tension knob until the inner borders of the fluorescein rings touch each other at the midpoint of their pulsation in response to 
Approval Date: 08-Jun-2020 17:02:44 (GMT )
19NOV2021 CSR 2007-301-[ADDRESS_427394]-T-01-01 v3.0the cardiac cycle. When this image is reached, the measurer takes his/her fingers off the tension 
knob and records the IOP reading along with the date and time of day in the source document.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE or SAE can be found in Appendix 2.
AEs will be reported by [CONTACT_2299].
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following up AEs that are serious, considered related to the study intervention or study procedures, or that caused the participant to discontinue the study intervention or study (see Section 7 ).
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All SAEs from the signing of the ICF until [ADDRESS_427395] dose of study intervention will 
be collected at the timepoints specified in the SoA ( Section 1.3), and as observed or reported 
spontaneously by [CONTACT_19288].
All AEs from the signing of the ICF until [ADDRESS_427396] dose of study intervention will be 
collected at the timepoints specified in the SoA (Section 1.3), and as observed or reported 
spontaneously by [CONTACT_19288].
Medical occurrences that begin before the start of study intervention, but after obtaining 
informed consent, will be recorded on the source document and transcribed onto the AE section of the eCRF and will be considered pretreatment AEs.
All SAEs will be recorded and reported to the sponsor or designee within 24 hours, as indicated 
in Appendix 2 . The investigator will submit any updated SAE data to the sponsor within 
24 hours of it being available.
Investigators are not obligated to actively seek AE or SAE information after conclusion of the 
study participation. However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention or study participation, the investigator must promptlynotify the sponsor.
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 2 .
8.3.2. Method of Detecting AEs and SAEs
Care will be taken to not introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427397]-T-01-01 v3.08.3.3. Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3).
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_41443]/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.
If a participant dies during participation in the study, the investigator will provide the sponsor or 
designee with a copy of any postmortem findings including histopathology.
New or updated information will be recorded in the originally completed eCRF.
The investigator will submit any updated SAE data to sponsor or designee within 24 hours of 
receipt of the information.
8.3.4. Regulatory Reporting Requirements for SAEs
!Prompt notification by [CONTACT_22836] 
a study intervention under clinical investigation are met. 
!The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, institutional review boards (IRBs), 
and investigators.
!An investigator who receives an investigator safety report describing an SAE or other specific safety information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the IB and will notify the IRB, if appropriate according to local 
requirements.
8.3.5. Pregnancy
!If a pregnancy is confirmed after the participant has received the study intervention, the participant may choose to exit the study after appropriate safety follow-up or to remain in the study for all safety and efficacy follow-up assessments through their Day 90/EarlyExit visit.
!Details of all pregnancies in female participants and, if indicated, female partners of male participants will be collected after the start of study intervention and through the duration of the pregnancy.
Approval Date: 08-Jun-2020 17:02:44 (GMT )
19NOV2021 CSR 2007-301-[ADDRESS_427398]-T-01-01 v3.0!If a pregnancy is reported, the investigator should inform the sponsor or designee within 
24 hours of learning of the pregnancy and should follow the procedures outlined in Appendix 6.
!Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) or genetic abnormalities (whether leading to an elective abortion or not) are considered SAEs.
8.3.6. Medication Errors
Medication error refers to any unintended error in the dosing and/or administration of the study
intervention as per instructions in the protocol. Medication errors generally fall into 3 categories 
as follows:
!Wrong study intervention
!Wrong dose (including dosing regimen, strength, form, concentration, amount)
!Wrong participant (ie, not administered to the intended participant)
8.4. Treatment of Overdose
Treatment of overdose is not applicable to this study.
8.5. Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study.
8.6. Pharmacodynamics
Pharmacodynamic parameters are not evaluated in this study.
8.7. Genetics
Genetics are not evaluated in this study.
8.8. Biomarkers and Other Assessments
8.8.1. Study Eye Drop Usage Questionnaire
The 2-question Study Eye Drop Usage Questionnaire will be completed by [CONTACT_344366] 1 (Baseline) and all follow-up visits to capture the date and time of their last study eye drop instillation and their overall compliance to study drop usage. 
Question 1: “What date and time did you last use your study eye drops?”
Question 2: “In general, did you use your study eye drops 3 times a day?” (yes / no)
Sites should review each participant’s response to ensure that the last instillation of their study
eye drops was ≥ 4 hours from the start of completing this questionnaire and that they are 
generally using their study eye drops 3 times per day. Should either of the participant’s responses 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427399].
8.9. Health Economics
Health economics are not evaluated in this study.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427400]-T-01-01 v3.09. Statistical Considerations
One database lock is planned for the study and will occur at the completion of the study. Detailed 
statistical analyses will be described in the analysis plan, which will be finalized prior to 
database lock.
9.1. Statistical Hypotheses
The null and alternative hypotheses for the primary efficacy endpoint are:
Superiority
!H0: The NATF (011516X) is not superior to Systane Ultra MD as measured by [CONTACT_344367] 90.
!HA: The NATF (011516X) is superior to Systane Ultra MD as measured by [CONTACT_344367] 90.
Noninferiority
!H0: The NATF (011516X) is inferior compared to Systane Ultra MD as measured by [CONTACT_344368] 90.
!HA: The NATF (011516X) is noninferior compared to Systane Ultra MD as measured by 
[CONTACT_344369] 90.
9.2. Sample Size Determination
The primary efficacy variable is change from baseline in total staining score at Day 90. Based on 
the assumption of noninferiority test for a between-group difference (ie, the noninferiority 
margin) of 2.[ADDRESS_427401] the above intervention difference with a power of 90% or greater at 
the 1-sided 1.25% significance level. Assuming a 15% dropout rate, [ADDRESS_427402] of participants as defined below:
!The intent-to-treat (ITT) population includes all randomized participants. Participants will 
be summarized according to the randomized study intervention.
!The per-protocol (PP) population includes all randomized participants who have no protocol deviations affecting the primary analysis. Participants will be summarized according to the randomized study intervention.
Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427403]-T-01-01 v3.0!The safety population includes all treated participants who receive/take ≥ 1 administration 
of study intervention. Participants will be summarized according to the study intervention 
they actually received.
9.4. Statistical Analyses
The statistical analysis plan (SAP) will be developed and finalized before database lock will 
describe the participant populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data. 
All data will be summarized with descriptive statistics and/or frequency tables. In general, 
nominal categorical data will be analyzed using Pearson’s chi-square test or Fisher’s exact test. 
Continuous variables will be analyzed using analysis of variance (ANOVA) models, 
mixed-effects model repeated measures (MMRM), or t-tests.
9.4.1. Efficacy Analyses
The efficacy analyses will be based on the ITT and PP population.
[IP_ADDRESS]. Analysis Endpoints
The primary and secondary efficacy endpoints are listed below and analyses will be defined in 
the following sections. All analyses for other efficacy/effectiveness endpoints listed below will be defined in the SAP.
Primary efficacy endpoint:
!Change from baseline in total staining score at Day 90
Secondary efficacy endpoint:
!Change from baseline in Current Symptom Survey (composite of all symptoms) at Day 90
Other efficacy endpoints:
!Change from baseline in corneal staining score
!Change from baseline in conjunctival staining score
!Change from baseline in total staining score other than Day 90
!Change from baseline in Current Symptom Survey (composite of all symptoms) other 
than Day 90
!Change from baseline in individual symptom scores from Current Symptom Survey
!Change from baseline in Schirmer test
!Change from baseline in TBUT 
!Change from baseline in Functional Vision Questionnaire, 5-Minute Blurry Vision, and Ocular Discomfort Questionnaire
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427404]-T-01-01 v3.0!Study Eye Drop Experience and Tolerability Questionnaire
In addition to those endpoints listed above, other analyses of exploratory efficacy such as 
responder analyses will be defined in the SAP.
[IP_ADDRESS]. Primary Analyses
The primary efficacy variable is the change from baseline in total staining score at Day 90.
The primary efficacy analysis will be performed in the ITT population using MMRM. The 
differences and the intervals will be constructed with the least squares means from the MMRM 
model with treatment, visit, visit by [CONTACT_9866], and baseline total staining stratum, and baseline total staining stratum by [CONTACT_344370]. In order to control the 
overall type I error rate in the primary efficacy analysis, the sequential procedures will be 
performed. Under this procedure, the noninferiority will be performed first and the superiority test will be performed next only if the null hypothesis of noninferiority is rejected. To test the 
hypothesis of noninferiority, a 2-sided 95% confidence interval will be constructed for the 
difference in the mean change from baseline in total staining at Day 90. If the upper limit of 2-sided CI is less than 2.[ADDRESS_427405] 
for superiority will be performed at the 0.05 significance level.
The primary efficacy variable will also be analyzed similarly on PP population as a sensitivity
analysis.
[IP_ADDRESS]. Secondary Analyses
The secondary efficacy variable is the change from baseline in Current Symptom Survey total 
score (composite of all symptoms) at Day 90. The secondary efficacy variable will be analyzed using MMRM.
[IP_ADDRESS]. Other Efficacy Analyses
Other efficacy analyses include comparing the NATF (011516X) with Systane Ultra MD at each 
scheduled visit on corneal staining, conjunctival staining, total staining score other than Day 90, 
Current Symptom Survey (composite of all symptoms) other than Day 90, individual symptom 
scores from Current Symptom Survey, Schirmer test, TBUT, Functional Vision Questionnaire, 5-Minute Blurry Vision and Ocular Discomfort Questionnaire, and Study Eye Drop Experience and Tolerability Questionnaire.
Change from baseline of selected continuous other efficacy variables will be analyzed using 
MMRM. Detailed methods for the analysis of other efficacy variables will be described in the SAP.
9.4.2. Safety Analyses
The safety analysis will be performed using the safety population and will be fully defined in the 
SAP.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427406]-T-01-01 v3.0The safety variables include AEs, biomicroscopy, currently corrected distance visual acuity, 
BCDVA, and IOP. All safety analyses will be conducted on the safety population. Medical 
Dictionary for Regulatory Activities (MedDRA) nomenclature will be used to code AEs. For each AE reported, the number and percent of participants will be tabulated. Separate tables will 
be generated for pretreatment AEs and treatment-emergent AEs. All AEs will be presented in the 
listings. Detailed analysis methods will be provided in the SAP.
Other safety variables, including biomicroscopy findings, currently corrected distance visual 
acuity, BCDVA, and IOP, will also be analyzed.
[IP_ADDRESS]. Adverse Events
An AE will be considered a treatment-emergent adverse event (TEAE) if:
!The AE began on or after the date of the first dose of study intervention; or
!The AE was present before the date of the first dose of study intervention, but increased in 
severity or became serious on or after the date of the first dose of study intervention
An AE will be considered a treatment-emergent SAE if it is a TEAE that additionally meets anySAE criteria.
The number and percentage of participants reporting TEAEs in each study intervention 
group/during the study will be tabulated by [CONTACT_344371], preferred term, and severity.
The number and percentage of participants reporting treatment-related TEAEs in each study
intervention group/during the study will be tabulated by [CONTACT_6657].
If more than [ADDRESS_427407] related occurrence for the summarizations by [CONTACT_325747].
Summary tables will be provided for participants with SAEs and participants with AEs leading to 
discontinuation if 5 or more participants reported such events. Listings of all AEs, SAEs, and AEs leading to discontinuation by [CONTACT_217664].
The definitions of an AE and SAE can be found in Appendix 2.
9.4.3. Other Safety Analyses
All other safety variables will be analyzed with descriptive statistics. Detailed methods for the 
analysis of other safety variables will be described in the SAP.
[IP_ADDRESS]. Subgroup Analyses 
The primary efficacy variable will also be analyzed by [CONTACT_245632].
9.5. Interim Analyses
Not applicable.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427408]-T-01-01 v3.09.5.1. Data Monitoring Committee
Not applicable.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427409]-T-01-01 v3.010. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
!This study will be conducted in accordance with the protocol and with the following:
oConsensus ethical principles derived from international guidelines including the 
Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines
oApplicable International Council on Harmonisation (ICH)/International Organization for Standardization (ISO)/Good Clinical Practice (GCP) guidelines
oApplicable laws and regulations
!The protocol, protocol amendments, ICF, IB, and other relevant documents (eg, advertisements) must be submitted to an IRB by [CONTACT_344372]. 
!Any amendments to the protocol will require IRB approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants. 
!The investigator will be responsible for the following:
oProviding written summaries of the status of the study to the IRB annually or more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_344373], for example 21 CFR, ICH guidelines, 
the IRB, and European regulation 536/2014 for clinical studies (if applicable)
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
Approval Date: 08-Jun-2020 17:02:44 (GMT )
19NOV2021 CSR 2007-301-[ADDRESS_427410]-T-01-01 v3.010.1.3. Informed Consent Process
!The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study. 
!Participants must be informed that their participation is voluntary. Participants will be required to sign a statement of informed consent that meets the requirements of 
[ADDRESS_427411] requirements, where applicable, and the IRB or study center. 
!The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.
!Participants must be re-consented to the most current version of the ICF(s) during their 
participation in the study. 
!A copy of the ICF(s) must be provided to the participant. 
10.1.4. Data Protection 
!Participants will be assigned a unique identifier. Any participant records or datasets that 
are transferred to the sponsor will contain the identifier only; participant names or anyinformation that would make the participant identifiable will not be transferred. 
!The participant must be informed that his/her personal study-related data will be used by[CONTACT_10999]. The level of disclosure must also be explained to the participant. 
!The participant must be informed that his/her medical records may be examined by[CONTACT_340764], by [CONTACT_42506], and by [CONTACT_6668].
10.1.5. Posting Clinical Study Data
!Study data and information may be published in nonpromotional, peer-reviewed publications either by [CONTACT_82298]. 
!Clinical study reports, safety updates, and annual reports will be provided to regulatoryauthorities as required.
!Company-sponsored study information and tabular study results will be posted on the 
[LOCATION_002] National Institutes of Health's website www.ClinicalTrials.gov and other 
publicly accessible sites.
Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427412]-T-01-01 v3.010.1.6. Data Quality Assurance
!All participant data relating to the study will be recorded electronic CRFs unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator 
is responsible for verifying that data entries are accurate and correct by [CONTACT_18027]. 
!The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF. 
!The investigator must permit study-related monitoring, audits, IRB review, and regulatoryagency inspections and provide direct access to source data documents. 
!The sponsor or designee is responsible for the data management of this study including quality checking of the data. 
!Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and anyother study agreements, ICH GCP, and all applicable regulatory requirements. 
!Records and documents, including signed ICFs, pertaining to the conduct of this studymust be retained by [CONTACT_344374]. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party without written notification to the sponsor. 
10.1.7. Source Documents
!Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the investigator’s site.
!Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study.
!Definition of what constitutes source data can be found in Section 4.0 of ICH E6, GCP: Consolidated Guidance and records must be attributable, legible, contemporaneous, original, and accurate .
10.1.8. Study and Site Closure
The sponsor or designee reserves the right to close the study site or terminate the study at any
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon studycompletion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427413]-T-01-01 v3.0The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by [CONTACT_11004]:
!Failure of the investigator to comply with the protocol, the requirements of the IRB or local health authorities, the sponsor’s procedures, or GCP guidelines
!Inadequate recruitment of participants by [CONTACT_093]
!Discontinuation of further study intervention development
10.1.9. Publication Policy
!Allergan as the sponsor has proprietary interest in this study. Authorship and manuscript composition will reflect joint cooperation between multiple investigators and sites and 
Allergan personnel. Authorship will be established prior to the writing of the manuscript. 
As this study involves multiple centers, no individual publications will be allowed prior to completion of the final report of the multicenter study except as agreed with Allergan.
!The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data.
!Authorship will be determined by [CONTACT_23531].
10.1.10. Compliance with Protocol
The investigator is responsible for compliance with the protocol at the investigational site. A 
representative of the sponsor will make frequent contact [CONTACT_78586]/her 
research staff and will conduct regular monitoring visits at the site to review participant and study intervention accountability records for compliance with the protocol. Protocol deviations 
will be discussed with the investigator upon identification. Significant protocol deviations will be 
reported to the IRB according to the IRB’s reporting requirements.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427414]-T-01-01 v3.010.3. Appendix 3: Abbreviations
Abbreviation Definition
AE adverse event
ANOVA analysis of variance
BCDVA best-corrected distance visual acuity
CDISC Clinical Data Interchange Standards Consortium 
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences 
CONSORT Consolidated Standards of Reporting Trials
DED dry eye disease
eCRF electronic case report form
EDS-VAS Eye Dryness Score - Visual Analog Scale
FDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
IB investigator’s brochure 
ICF informed consent form
ICH International Council on Harmonisation
IOP intraocular pressure
IRB institutional review board
ISO International Organization for Standardization
ITT intent-to-treat
IxRS interactive response system
KCS keratoconjunctivitis sicca
LASIK laser-assisted in situ keratomileusis
MD multidose
MedDRA Medical Dictionary for Regulatory Activities 
MMRM mixed-effects model repeated measures
N/A not applicable
NCI National Cancer Institute
OD right eye
OHT ocular hypertension
OS left eye
OSDI Ocular Surface Disease Index® Questionnaire
OTC over-the-counter
NATF new artificial tear formulation
NEI National Eye Institute
PP per-protocol
SAE serious adverse event
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427415]-T-01-01 v3.0Abbreviation Definition
SAP statistical analysis plan
SoA schedule of activities
TBUT tear break-up time
TEAE treatment-emergent adverse event
US [LOCATION_002]
VAS visual analog scale
vs versus
WOCBP woman of childbearing potential
Approval Date: 08-Jun-2020 17:02:44 (GMT )
19NOV2021 CSR 2007-301-[ADDRESS_427416]-T-01-01 v3.010.4. Appendix 4: Standard Discontinuation Criteria
This table provides participant discontinuation criteria for this protocol. Clinical Data 
Interchange Standards Consortium (CDISC) terminology is used, and thus subject or patient is 
used instead of participant (as used elsewhere in this protocol). These terms are interchangeable.
CDISC Submission Value CDISC Definition
AE Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. For further information, see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting (modified from ICH E2A) Synonyms: side effect, 
adverse experience. See also serious adverse event, serious adverse 
experience. (CDISC glossary)
Completed To possess every necessary or normal part or component or step; having come or been brought to a conclusion (NCI)
Death The absence of life or state of being dead (NCI)
Disease relapse The return of a disease after a period of remission
Failure to meet randomization criteria An indication that the subject has been unable to fulfill/satisfy the 
criteria required for assignment into a randomized group
Lack of efficacy The lack of expected or desired effect related to a therapy (NCI)
Lost to follow-up The loss or lack of continuation of a subject to follow-up
Noncompliance with study drug An indication that a subject has not agreed with or followed the 
instructions related to the study medication (NCI)
Other Different than the one(s) previously specified or mentioned (NCI)
Physician decision A position, opi[INVESTIGATOR_1649], or judgment reached after consideration by a 
physician with reference to subject (NCI)
Pregnancy Pregnancy is the state or condition of having a developi[INVESTIGATOR_182515] (uterus), after union of an ovum and spermatozoon, during the period from conception to birth. (NCI)
Progressive disease A disease process that is increasing in extent or severity (NCI)
Protocol deviation An event or decision that stands in contrast to the guidelines set out 
by [CONTACT_760] (NCI)
Recovery A healing process and/or an outcome implying relative health. The 
term is typi[INVESTIGATOR_344348]. (NCI)
Screen failure The potential subject who does not meet one or more criteria 
required for participation in a trial
Site terminated by [CONTACT_78588] a clinical study was stopped at a particular site 
by [CONTACT_23662] (NCI)
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427417]-T-01-01 v3.0CDISC Submission Value CDISC Definition
Study terminated by [CONTACT_78588] a clinical study was stopped by [CONTACT_23662] 
(NCI)
Technical problems A problem with some technical aspect of a clinical study, usually 
related to an instrument (NCI)
Withdrawal by [CONTACT_7078]/guardian An indication that a study participant has been removed from the 
study by [CONTACT_336113] a study participant has removed itself from the 
study (NCI)
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427418]-T-01-01 v3.010.5. Appendix 5: Study Tabular Summary
This table is intended for use in posting study information to registries (eg, ClinicalTrials.gov).
Parameter Group Parameter Value
Study information Study Title A Multicenter, Single-masked, 
Randomized Study to Compare the 
Efficacy and Safety of a New
Artificial Tear Formulation (011516X)with Systane
®Ultra Multidose for [ADDRESS_427419] Indicator No
Planned Minimum Age of Subjects 18
Planned Maximum Age of Subjects Not specified
Sex of Participants Both
Stable Disease Minimum Duration Not specified
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427420]
Added on to Existing Treatments No
Control Type Active
Comparative Treatment Name [CONTACT_344379] 2
Study Is Randomized Yes
Randomization Quotient 1:1
Study Blinding Schema Single-masked
Stratification Factor Total ocular staining score of the study 
eye (mild/moderate = score of 6 to 25 
vs severe = score of 26 to 43)
Adaptive Design No
Study Stop Rules None
Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427421]-T-01-01 v3.010.6. Appendix 6: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).
Women in the following categories are not considered WOCBP:
1. Premenarchal
2. Premenopausal female with 1 of the following:
!Documented hysterectomy
!Documented bilateral salpi[INVESTIGATOR_1656]
!Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s: review of the participant’s 
medical records, medical examination, or medical history interview.
3. Postmenopausal female
!A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. 
Contraception Guidance:
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective or acceptable method of contraception consistently and correctly as described in 
Table 10-1.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427422]-T-01-01 v3.0Table 10-1 Highly Effective and Acceptable Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of < 1% per year when used consistently and correctly
Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation 
!Oral 
!Intravaginal 
!Transdermal 
Progestogen-only hormonal contraception associated with inhibition of ovulation
!Oral 
!Injectable 
Highly Effective Methods That Are User Independenta
!Implantable progestogen-only hormonal contraception associated with inhibition of ovulation
!IUD
!IUS
!Etonogestrel implant (ie, Nexplanon®)
!Bilateral tubal occlusion (eg, Essure®, bilateral tubal ligation)
!Intrauterine copper contraceptive (ie, ParaGard®)
Vasectomized Partner 
A vasectomized partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.
Sexual Abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
Acceptable Methods
Acceptable birth control methods that result in a failure of more than 1% per year include:
!Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of 
action
!Male or female condom with or without spermicide
!Cap, diaphragm, or sponge with spermicide
!Nonhormonal intrauterine device
Combinations of male condom with either cap, diaphragm, or sponge with spermicide (double-barrier methods) are also considered acceptable, but not highly effective, birth control methods.
aTypi[INVESTIGATOR_35818]. Use should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427423]-T-01-01 v3.0Pregnancy Testing:
!WOCBP should only be included after a negative highly sensitive urine pregnancy test at 
screening.
!Additional pregnancy testing should be performed at study exit, and as required locally.
!Pregnancy testing will be performed when pregnancy is otherwise suspected. 
!Urine pregnancy testing will be used unless the study site requires the use of serum testing, in which case serum testing will be used.
Collection of Pregnancy Information:
Female Participants Who Become Pregnant
!The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to Allergan within 24 hours of learning of a participant’s pregnancy. The participant will be followed to determine the outcome of the pregnancy. 
The investigator will collect follow-up information on the participant and the neonate, and 
the information will be forwarded to Allergan. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) 
or indication for the procedure.
!While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication will be reported as an AE or SAE. Abnormal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) or genetic 
abnormalities (whether leading to an elective abortion or not) are always considered to be SAEs and will be reported as such. Any poststudy pregnancy-related SAE considered 
reasonably related to the study intervention by [CONTACT_344375] 8.3.4 . While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through spontaneous reporting.
!If a pregnancy is confirmed after the participant has received study treatment, the participant may choose to exit the study after appropriate safety follow-up or to remain in the study for all safety and efficacy follow-up assessments through the end-of-study visit.
Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427424]-T-01-01 v3.010.7. Appendix 9: Study Schedule Supplement
10.7.1. Screening (Day -7 [-3 days])
!Written informed consent and written documentation in accordance with the relevant 
country and local privacy requirements 
!Demographic information
!Medical and ophthalmic histories
!Inclusion/exclusion criteria assessment
!Self-assessed surveys/questionnaires: Current Symptom Survey and OSDI Questionnaire
!Adverse event assessment
!Prestudy medication assessment
!Urine pregnancy test (for WOCBP only)
!Currently corrected distance visual acuity, BCV A, biomicroscopy, TBUT (with fluorescein), corneal staining (modified NEI grading, with fluorescein), conjunctival staining (modified NEI grading scheme, with lissamine green), Schirmer test (with 
anesthesia), and IOP (with anesthesia and fluorescein using a Goldmann applanation 
tonometer)
!Access IxRS
!Dispense run-in medication (if the patient meets the required Day -7 [Screening] qualifications) 
Patients who fulfill all inclusion and exclusion criteria should be dispensed the run-in 
medication, REFRESH PLUS. They should be given instructions regarding the method of instillation and the dose regimen to be followed.
10.7.2. Baseline (Day 1)
!Inclusion/exclusion criteria assessment
!Medical and ophthalmic histories
!Concomitant medication assessment
!Adverse event assessment
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427425]-T-01-01 v3.0!Self-assessed surveys/questionnaires: Study Eye Drop Usage Questionnaire, Current 
Symptom Survey, OSDI Questionnaire, and Functional Vision Questionnaire
!Currently corrected distance visual acuity, biomicroscopy, TBUT (with fluorescein), corneal staining (modified NEI grading, with fluorescein), conjunctival staining 
(modified NEI grading scheme, with lissamine green), Schirmer test (with anesthesia), 
and IOP (with anesthesia and fluorescein using a Goldmann applanation tonometer, only for participants with glaucoma or OHT)
!Monitor return of unused run-in medication and confirmation of run-in medicationaccountability
!Access IxRS 
!Randomization
!Predose and postdose 5-Minute Blurry Vision and Ocular Discomfort Questionnaire
!Dispense study medication (if the participant qualifies for the study)
10.7.3. Day 7 (±3 days)
!Self-assessed surveys/questionnaires: Study Eye Drop Usage Questionnaire, Current Symptom Survey, OSDI Questionnaire, Study Eye Drop Experience and Tolerability
Questionnaire, and Functional Vision Questionnaire
!Adverse event assessment
!Concomitant medication assessment
!Currently corrected distance visual acuity, biomicroscopy, TBUT (with fluorescein), 
corneal staining (modified NEI grading, with fluorescein), conjunctival staining (modified NEI grading scheme, with lissamine green), Schirmer test (with anesthesia), 
and IOP (with anesthesia and fluorescein using a Goldmann applanation tonometer, 
only for patients with glaucoma or OHT)
10.7.4. Days 30 and 60 (±7 days)
!Self-assessed surveys/questionnaires: Study Eye Drop Usage Questionnaire, Current Symptom Survey, OSDI Questionnaire, Study Eye Drop Experience and Tolerability
Questionnaire, and Functional Vision Questionnaire
!Adverse event assessment
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427426]-T-01-01 v3.0!Concomitant medication assessment
!Currently corrected distance visual acuity, biomicroscopy, TBUT (with fluorescein), 
corneal staining (modified NEI grading, with fluorescein), conjunctival staining (modified NEI grading scheme, with lissamine green), Schirmer test (with anesthesia), 
and IOP (with anesthesia and fluorescein using a Goldmann applanation tonometer, 
only for patients with glaucoma or OHT)
!Monitor return of used and unused study intervention and confirmation of studyintervention accountability
!Access IxRS
!Dispense study intervention
10.7.5. Day 90/Early Exit (±7 days)
!Self-assessed surveys/questionnaires: Study Eye Drop Usage Questionnaire, Current Symptom Survey, OSDI Questionnaire, Study Eye Drop Experience and TolerabilityQuestionnaire, and Functional Vision Questionnaire
!Adverse event assessment
!Concomitant medication assessment
!Urine pregnancy test (for WOCBP only)
!Currently corrected distance visual acuity, BCV A, biomicroscopy, TBUT (with fluorescein), corneal staining (modified NEI grading, with fluorescein), conjunctival staining (modified NEI grading scheme, with lissamine green), Schirmer test (with anesthesia), and IOP (with anesthesia and fluorescein using a Goldmann applanation 
tonometer, only for patients with glaucoma or OHT)
!Access IxRS
!Predose and postdose 5-Minute Blurry Vision and Ocular Discomfort Questionnaire
!Monitor return of used and unused study intervention and confirmation of study
intervention accountability
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427427]-T-01-01 v3.010.8. Appendix 10: Protocol Amendment History
The protocol amendment summary of changes table for the current amendment is located 
directly before the TOC.
Amendment 1 (February 2020)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
because it neither significantly impacts the safety or physical/mental integrity of participants nor the scientific value of the study.
Overall Rationale for the Amendment:
The overall rationale for the changes implemented in Protocol Amendment 1 is to remove the 
evaluation of a second new artificial tear formulation (NATF) formulation (011533X) from the study.
Section Number and Name [CONTACT_344380], Section 1 Synopsis, Figure 1-1, 
Section 2.1 Study Rationale, Section 2.2 Background, Section 2.3 Benefit/Risk Assessment, Section 3 Objectives and Endpoints, Section 4.1 Overall Design, Section 4.2, Scientific Rationale for Study 
Design, Section 6.1 Study Interventions 
Administered, Section 6.1.3 Instructions for Use and Administration, Section 6.3 Measures to Minimize Bias: Randomization and Masking, Section 6.4 Study 
Intervention Compliance, Section 9.1 
Statistical Hypotheses, Section [IP_ADDRESS] Other Efficacy Analyses, Section 10.5 
Appendix 5: Study Tabular SummaryRemoved the NATF formulation 011533X arm from the study. Administrative decision to 
focus development efforts and resources on a single 
formulation. 
Section [ADDRESS_427428] 340 participants (170 participants 
in each arm) complete the study 
through Day 90, assuming an 
approximate 15% dropout rate.Because the study is 
changing from a 3-arm to a 2-arm study, a smaller number of participants will 
be required. 
Section 1 Synopsis, Section 4.1 Overall 
Design, Section 5 Study Population, 
Appendix 5 Study Tabular SummaryChanged the number of study 
sites from up to 40 sites to 
approximately 28 sites. Because the study is 
changing from a 3-arm to a 2-arm study and a smaller number of participants will be required, a smaller number of sites will be 
required.
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427429]-T-01-01 v3.0Section Number and Name [CONTACT_19523] 5.1 Inclusion Criteria Revised inclusion criterion 2.01 
as follows: At the Screening 
(Day -7) and Baseline (Day 1) 
visits, at least [ADDRESS_427430] qualify at both visits:For clarification.
Section 5.2 Exclusion Criteria Added the following exclusion 
criterion 1.02: At the Screening 
(Day -7) or Baseline (Day 1) 
visits, one or both eyes have
• Corneal staining score of 5 in 
any of the 5 zones or a total score 
of <5 or > 19 based on the 
modified NEI grading scheme 
(score range = 0 to 5; graded in 
5 zones of the cornea for a total 
score range of 0 to 25)
or
• Conjunctival staining score of 5 
in any of the 6 zones based on the 
modified NEI grading scheme 
(score range = 0 to 5 per zone)For clarification.
Section [IP_ADDRESS] Corn eal Staining (Modified 
NEI Grading Scheme, with Fluorescein)Revised the following text; 
Fluorescein staining will be 
evaluated using a slit-lamp with 
full slit width and approximately 
10X to 16X magnification with 
cobalt blue illumination and a yellow barrier filter to enhance 
contrast.For clarification. 
Section [IP_ADDRESS] Conjun ctival Staining 
(Modified NEI Grading Scheme, with Lissamine Green)Revised the following text: Using 
the white light of low to moderate 
intensity, tThe 6 conjunctival 
regions (3 nasal and 3 temporal) will be graded using the modified 
NEI grading scheme (score between 0 and 5 per region) yielding a maximum possible 
score per eye of 30.For clarification.
Approval Date: 08-Jun-2020 17:02:44 (GMT )
19NOV2021 CSR 2007-301-[ADDRESS_427431]-T-01-01 v3.0Section Number and Name [CONTACT_19523] 9.1 Statistical Hypotheses Revised the following text: 
•H 0: The NATF (011516X) is 
not noninferior compared to 
Systane Ultra MD as measured by 
[CONTACT_344376] 90.For clarification.
Section [IP_ADDRESS] Primary Analyses Revised the following text: 
In order to control the overall type I error rate in the primary 
efficacy analysis, the Hochberg 
Bonferroni reverse fixed 
sequencesequential procedures 
will be used since performed. 
Under this procedure, the null 
hypotheses of noninferiority are 
nested in will be performed first 
and the null hypotheses of
superiority. Under this procedure,
test will be performed next only if 
the null hypothesis of superiority 
is rejected using Hochberg test 
the null hypothesis of 
noninferiority is automatically 
rejected, and if the null 
hypothesis of superiority is not 
rejected using Hochberg 
procedure the null hypothesis of 
noninferiority is tested using 
Bonferroni test. For each NATF 
tear formulation, test for 
superiority will be performed first 
by [CONTACT_344377]’s 
procedure at 0.[ADDRESS_427432] the 
hypothesis of noninferiority, a 2-
sided 97.595% confidence 
intervalsinterval will be 
constructed for the difference in the mean change from baseline in total staining at Day 90. If the upper limit of 2-sided CIsCI is 
less than 2.[ADDRESS_427433] for 
superiority will be performed at 
the 0.05 significance level.Because the study is changing from a 3-arm to a 2-arm study, the primary analysis methods were 
updated. 
Approval Date: 08-Jun-2020 17:02:44 (GMT ) Approval Date: 08-Jun-2020 17:02:44 (GMT)
19NOV2021 CSR 2007-301-[ADDRESS_427434]-T-01-01 v3.011. References
Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, et al. Dysfunctional tear 
syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25(8):900-907.
Craig JP, Nichols KK, Akpek EK, Caffery HS Dua, Joo CK, Liu ZJ, Nelson JD, Nichols JJ, 
Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. Ocul Surf. 
2017;15(3):276-283.
Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX. TFOS DEWS II 
Management and Therapy Report. Ocul Surf. 2017;15(3):575-628.
Lemp MA. National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes, CLAO J 
1995;21:221-232.
Pflugfelder S. Baylor Fluorescein Corneal Staining Scheme (Unpublished Personal
Communication, 2008).
Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II 
Epi[INVESTIGATOR_344349]. Ocul Surf. 2017;15(3):334-365. 
Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of DED: 
The interaction between the ocular surface and lacrimal glands. Cornea 1998. 
doi:10.1097/00003226-199811000-[ZIP_CODE].
Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II 
Diagnostic methodology report. Ocul Surf. 2017;15(3):539-574.
Approval Date: 08-Jun-2020 17:02:44 (GMT )
19NOV2021 CSR 2007-301-005 80